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ABSTRACT OF THE DISSERTATION
The Influence of Low Dietary Fat Intake on Incidence
and Severity of Migraine Headache

by

Zuzana Bic
Doctor of Public Health in Preventive Care
Loma Linda University, Loma Linda California, 1997
Associate Professor Glen G. Blix, Dr. PH., Chairman

Migraine headaches are a common and debilitating syndrome causing
untold suffering and loss of productivity. A review of the literature indicates that
there are two primary factors involved in triggering these headaches: high levels
of blood lipids and high levels of free fatty acids. Under these conditions platelet
aggregability is increased, which is associated with decreases in serotonin and
heightened prostaglandins levels. These conditions may produce vasodilation, the
most immediate precursor to migraine headache. A high fat diet is one factor that
may directly affect this process. This study was undertaken to evaluate the impact
of dietary fat intake on incidence and severity of migraine headache.
Methods: The study was conducted over a 12 week period on 54 previously
diagnosed migraine headache patients. During the first 28 days the study subjects
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recorded all food consumption in a diet diary and maintained a headache diary. At
the conclusion of this 28 day baseline period subjects were individually counseled
to limit fat intake to no more than 20 grams per day. A 28 day run-in period was
then allowed for adaptation to the low fat diet. Study results are reported on a
final 28 day post-intervention period.
Results: The decreased fat dietary intervention was associated with a
statistically significant (p< 0.0001) decrease in headache frequency, intensity,
duration, and medication intake. There was a significant positive correlation
between dietary fat intake and headache frequency (r=0.70, p<0.0001), intensity
(r=0.72, p<0.0001), headache index (r=0.65, p<0.0001), and medication intake
(r=0.67, p<0.0001). Subjects significantly decreased (p<0.0001) the ingestion of
dietary fat (in grams) between baseline (mean=65.9, pcO.OOOl) and the post
intervention period (mean=27.8).
Conclusion: This study indicates that a low fat diet can reduce headache
frequency, intensity, duration and medication intake.
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CHAPTER 1
Definition of the Problem
Migraine headache is an idiopathic reoccurring headache disorder with a
lateralized, pulsating quality of pain, sometimes associated with nausea, vomiting,
and with or without visual disturbances. Migraine headache is, unfortunately, an
all too common and painful experience for many American adults. Currently, 5 to
10 percent of the population seek intermittent aid for relief of disabling headache,
and over 40 percent of North Americans have experienced severe headache at
some point in their lives (Ziegler, 1977).
A reasonable estimate of the annual prevalence of migraine in the Western
world is 30 percent in women aged 21 to 34 years, declining to 10 percent in those
75 years old and beyond. The respective estimates for men in the same age ranges
are 17 percent and 5 percent (Waters, 1986).
Over 90 percent of patients with migraine report that their first attack
occurred before the age of 40 years (Selby, 1960). A study by Whitty and Hockday
(1968) reported that only half of the patients over the age of 64 years continued to
have attacks. Neither the age at onset nor the total duration of the disorder bore a
clear relation to the persistence or cessation of attacks.
Over 80 percent of cases with severe migraine headache experience mild,
moderate, or severe disability (requiring bedrest) related to their headaches
(Stewart, 1991; Stewart, 1994). Osterhaus (1990) reported that 55 percent of
subjects with migraine headache in his study missed 2 work days per month,
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and 88 percent worked 5.6 days per month with migraine symptoms that reduced
their productivity. Solomon (1993) found that while chronic headache patients
may be physically able to function, they routinely function at a level significantly
below their normal capabilities.
In spite of the prevalence of the syndrome the medical community has yet to
achieve consensus on the treatment or underlying causes of migraine headache. The
etiology of the problem has received scant attention. Medical literature dealing with
these painful headaches has concentrated on symptomatic relief rather than seeking
to elucidate the causes. A recent overview of migraine headache treatment by Lance
(1990) suggests a management of migraine headache that concentrates on
symptomatological factors, recommends the development of additional
pharmacological agents and even considers an invasive surgical intervention rather
than viewing migraine headache as a sign of biochemical imbalance in the body. On
the other hand, Norman Cousins (1979) suggested that the most ignored fact about
pain is that it is best eliminated by discontinuing the underlying abuse causing the
pam.
There are several known states that occur during migraine headache which
are described below:
1. A study by Anthony et al. (1969), demonstrated that plasma serotonin
dropped during a migraine attack. Migraine headache can thus be described as a
state of low serotonin (Davidoff, 1995). Any mechanism which increases serotonin
levels or minimizes its release from platelets can minimize migraine headache.

2

Carbohydrate consumption has also been shown to increase serotonin synthesis
(Liebermann et al., 1986). A study by Salmon et al. (1978) justifies headache
therapy with 5-HT (serotonin) whose precursor is tryptophan. Migraine attacks
discussed by Waldenlind et al. (1985) were associated with reduced plasma 5-HT
concentrations, with a reaction releasing serotonin from platelets, a temporary
presence of a 5-HT releasing factor in the plasma, and an increased excretion of the
metabolite 5-hydroxyindo-leacetic acid (a serotonin metabolite) in the urine in many
patients. The mechanism of serotonin release from platelets is due to mechanical
trauma, blood clotting factors, and various fatty acids.
The factor that releases serotonin from platelets has a molecular weight of
less than 50,000. It is, therefore, probably not a protein, but rather a free fatty acid
(FFA) such as stearic, linoleic, palmitic, or oleic acid, each of which may qualify as a
platelet serotonin releaser (Anthony, 1978). In summary, serotonin is a
neurotransmitter which at low levels can trigger vasodilatation and migraine
headache.
2. Migraine headache is also described as a state in which free fatty acids
(FFA) in the blood are increased. Any mechanism which decreases free fatty acids
levels in the blood may minimize migraine headache. Silberstein (1994) evaluated
plasma free fatty acids (FFA) and serotonin before, during, and after a migraine
attack and showed that in the majority of cases, where serotonin levels fell during a
headache, there was a simultaneous rise of plasma free fatty acids. Researchers
found high platelet aggregability and hyperlipidemia in connection with serotonin
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release from platelets during a migraine headache. Hypercoagulability was found in
blood taken from human subjects after a meal of high fat content, and the addition
of certain fatty acids to plasma accelerates the clotting time (Shore, 1963). A study
by Hassall et al. (1983) showed that platelets are hyperaggregable in the presence of
elevated LDL-C, both in vitro and in vivo. Carravalho et al. (1974) showed that high
levels of LDL-C and/or low levels of HDL-C may be etiologically related to migraine,
possibly due to platelet hyperagregability and/or the increased likelihood of cerebral
biochemical changes. The same study also states that diets rich in saturated fat
elevate the LDL-C levels, which tend to increase platelet aggregation.
Even though it has been demonstrated that increased levels of free fatty
acids in the blood, hyperlipidemia, and low levels of serotonin occur in migraine
headache patients, little is known about the possible effect of a low fat diet (which is
a known factor for decreasing blood lipid levels) as a treatment for migraine
headache. The gap in the literature on the connection between laboratory findings
during migraine headache and dietary fat intake intervention suggests the need for
a study on low fat diet and its effect on migraine headache. An elevated lipid profile
which is influenced by high dietary fat intake is the first step in influencing the
platelet disturbance process and the other changes which follow due to platelet
damage. Platelets are a storehouse for serotonin and other substances. If there is
damage to the platelets these stored components are released into the plasma and
may cause vasodilatation that precedes migraine headache. A low fat diet can
directly decrease blood lipid levels and lower FFA, thus lowering platelet
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aggregability and stopping or minimizing other biochemical changes that trigger
migraine headache.
Purpose of the Study
The purpose of this study was to determine whether a low fat diet can
decrease the frequency, intensity, and duration of migraine attacks. Dietary
modification seemed an attractive intervention due to low cost, decreased risk of
addiction and dependency on pain medication, and decreased risk for development
of other chronic diseases and cancer.
Part of the "magic cure" for migraine headache may be found by changing
eating habits to a low dietary fat thus decreasing level of free fatty acids in the blood
and subsequently altering the release of serotonin from the platelets. Changes in
this substance have been implicated in triggering migraine headache. A low fat diet
treatment is a new approach for the management of migraine headache that focuses
on the etiology of migraine rather than just an alleviation of the symptoms.
Research Questions
The primary research questions are:
1. What is the etiology of migraine headache? Is there a common denominator for
different factors in triggering migraine headache?
2. Does a low fat dietary intake decrease frequency, intensity and duration of
migraine headache?
3. Does a low fat dietary intake decrease the usage of pain killer medications?
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Strengths and Limitations of the Study
This study was conducted, using objective measurements to overcome
possible subjective bias, and was conducted over a sufficient time to reduce
significant biases connected with social desirability Below is a discussion of the key
strengths and weaknesses of this research.
1. This study was based on a quasi-experimental design. Quasi-experiments
have treatments, outcome measures, and experimental units, but do not use
random assignment to create a comparison from which treatment-caused change is
inferred. Random assignment to control and experimental groups was not possible
due to ethical considerations. Subjects experiencing pain were anxious to receive the
dietary treatment as soon as possible in order to alleviate their suffering.
Furthermore, subjects not involved in a dietary intervention would not likely have
kept food diaries for the duration of the study. Each of subjects had the same
opportunity to change their eating habits after a baseline period. All subjects with
migraine headache who signed up for the study and who were eligible according to
the study requirements were accepted. Subjects served as their own controls with
each being tracked for four weeks of baseline, followed by eight weeks of dietary
intervention.
2. The study did not "blind" the investigator to the research hypotheses. The
study was based on a dietary intervention, and was guided by individual dietary
counseling by a single research investigator. Because the investigator was not blind
to the research hypothesis, it is possible that reported changes in dietary fat intake
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and migraine attack in the subjects was in part due to the investigator's bias.
However, since the study took place over 12 weeks there was less likelihood of
subjects’ prolonging attempts to report only socially desired behaviors and live up to
the investigator's expectations. Objective measurements, such as weight and percent
of body fat, were used to help ameliorate possible bias and validate self-reported
behavior.
3. The study used a "real world" environment rather than a closed laboratory
environment. In a closed environment it would have been possible to more closely
control subjects' food intake. In the free living environment this was not possible,
but it has the advantage of testing a real situation. By administering objective
measurements, such as weight and percent of body fat, it was possible to control
some of the potential bias in food diaries.
4. The Hawthorne Effect was a possible limitation of the study. Awareness of
being in a research study is typically considered to elicit socially desirable responses
(such as greater satisfaction, or lessening in reporting headache)
(Cook & Campbell, 1979). It was necessary to tell subjects about the expectations of
dietary intervention on migraine headache in order to provide the rationale for
changing their eating habits, for maintaining a low fat diet, and monitoring the
occurrence of migraine headache. To minimize the Hawthorne Effect, objective
measurements, such as weight and percentage of body fat, were taken to validate
adherence to the low fat diet. The entire study took place over 12 weeks which
helped to decrease subjects’ attempts at reporting socially desired behaviors. Past
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research on headache diaries shows a good correlation between ratings by
significant others (the person with whom the patient lives) and the scores recorded
in the patient’s headache diary Thus it appears that the headache diary is valid, and
improvement detected is also noticeable by the significant other with whom the
patient lives (Blanchard & Andrasik, 1985).
5. The Rosenthal Effect was another possible limitation of the study (Cook &
Campbell, 1979). Awareness of being praised or the wish to please the investigator
can force the patient to report changes in order to satisfy the investigator. In this
study only one research investigator served as both the investigator and
interventionist. It is possible that patients attempted to present themselves in a
pleasing manner to the investigator by reporting improvements in food and
headache diaries. However the study was conducted over 12 weeks and objective
measurements were performed. Both the length and the objective measurements
(such as weight, percent body fat) support the accuracy of the subject's food and
headache diaries and therefore minimize this bias.
Definitions
The following terms were used in the research articles:
Free fatty acids: Exist in the body either as free, unesterified, or as fatty acyl
esters in more complex molecules. Free fatty acids such as stearic, palmitic, linoleic,
and oleic could qualify for releasing of serotonin in vitro (Anthony, 1978). During
and after migraine headache attack there was a rise of plasma free fatty acids
(Silberstein, 1994).
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Insulin: A peptide hormone, secreted by the pancreatic islets of Langerhans.
It promotes glucose entry into most cells of the body, in this way controlling the rate
of metabolism of most carbohydrates (Guyton, 1987). It also promotes protein
synthesis and the formation and storage of neutral lipids. If there is low level of
insulin, the amount of free fatty acids (product from lipid metabolism) increases in
the blood.
Insulin resistance: Non-response or lack of insulin which activates hormonesensitive lipase and causes rapid mobilization of fatty acids. When carbohydrates are
not available in the diet, insulin secretion diminishes, and this in turn promotes fatty
acid metabolism (Guyton, 1987). Insulin resistance causes hyperglycemia and low
uptake of glucose by cells.
Lipid profile: A blood test for very low density (VLDL), low density
lipoproteins (LDL), high density lipoproteins (HDL), and total cholesterol level
(Campe et al., 1987).
Low density lipoproteins (LDL): Providers of cholesterol to the peripheral
tissue. Lipoproteins function both to keep lipids soluble as they transport the lipids
in the serum, and to provide an efficient mechanism for delivering their lipid
contents to the tissues. The low density lipoprotein reflects the dietary fat intake,
and is known as "bad type" and is high in obese patients (Campe et al., 1987).
Migraine headache: An idiopathic, reoccurring headache disorder
manifesting in attacks lasting usually 4-72 hours. Typical characteristics of
headache are of unilateral location, pulsating quality, moderate or severe intensity,
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aggravation by routine physical activity, and association with nausea, photo- and
phono-phobia (increased sensitivity to light and noise). Changes in blood
composition and platelet function initiated endogenously by environmental
influences may play a triggering role. There are two types of migraine headache:
without aura and with aura. The migraine headache with aura usually develops
over 5-20 minutes with one or more fully developed aura symptoms indicating focal
cerebral cortical and/or brain stem function (visual loss, scotoma, distortion of
vision, numbness, unilateral paresthesia affecting face, hands, hemiparesis or
aphasia). For migraine headache classification definitions from Headache
Classification Committee of the International Headache Society were used (Olesen,
1989).
Monoaminooxidase (MAO): A mitochondrial enzyme. Platelet MAO activity
is significantly reduced in migraine patients. There are two types of MAO. Type A
predominates in the human intestinal mucosa and liver, and preferentially
inactivates catecholamines and serotonin. The human platelets contain only type B
which inactivates phenylethylamine, benzylamine, and methylhistamine. Tyramine
and dopamine are substrates for both forms (Olesen et al., 1993).
Obesity: An abnormal increase of fat in the subcutaneous connective tissue.
Obesity is equal to > 20 percent over ideal weight. Obesity is also equal to > 20
percent of body fat for men and > 30 percent of body fat for women. The increased
fat in the subcutaneous tissue correlates positively with plasma free fatty acids
concentration (Groop et al., 1991).

10

Omega-6: A polyunsaturated fatty acid -- linoleic acid is the primary member
of this group. Sources include vegetable oils.
Percent body fat: The usage of skinfold measurements for calculating the
percentage of body fat (Nieman, 1990). In this study the 7-site measurements were
used for percent body fat calculation.
Platelets: Minute round or oval discs, 2 to 4 microns in diameter. They are
formed in the bone marrow. In the cytoplasm of platelets there are active factors
such as enzyme systems, systems that synthesize prostaglandins, serotonin, proteinfibrin stabilizing factor, growth factor etc. Platelets also function as storage for the
neurotransmitter serotonin (Guyton, 1987).
Platelet aggregability: Occurs when the vascular endothelium is damaged
and circulating platelets aggregate at the site of the injury. This clumping of
platelets is accompanied by the release of a number of compounds from the platelets
(such as serotonin) which are involved in the process of migraine headache (Olesen
et al., 1992). Prostaglandins: Are physiologically active substances present in many
tissues (first found in accessory gland). Prostaglandins cause vasodilatation. Dietary
precursors for prostaglandins are linoleic acid, and for the predominant classes of
prostaglandins it is arachidonic acid. Excess production of prostaglandins results in
a diverse group of symptoms, including pain, inflammation, fever, nausea, and
vomiting (Campe et al., 1987).
Pyridoxine (B6): A vitamin used as a coenzyme of the amino acid
decarboxylase. Pyridoxine decreases consequently with decreased levels of serotonin
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during migraine headache. The decarboxylation of the 5-hydroxytryptophan (the
precursor of serotonin) is decreased in pyridoxine deficiency (Wurtman et al., 1979).
Serotonin (5-HT): A potent vasoconstrictor, neurotransmitter, that is
secreted by nuclei of the brain stem and is projected to many brain areas. It is
stored in platelets. During platelet aggregation, serotonin is released from platelets
and degraded by monoaminooxidase, therefore there is not enough serotonin for
brain uptake. Serotonin acts also as an inhibitor of pain pathways. Low levels of
serotonin cause vasodilatation and promote other mechanisms for the migraine
headache pathway (Guyton, 1987).
Thiamine (Bl): A vitamin important in carbohydrate metabolism, and
during migraine headache. Lower levels cause a diminished capacity to tolerate
stress (Wurtman et al., 1979).
Thromboxane: Thromboxane A2 promotes platelet aggregation, produced
primarily by platelets. Thromboxane A3 is a weak platelet aggregator (Hassall et al.,
1983). Increased platelet aggregation promotes serotonin release from platelets,
followed by vasodilatation. All are connected with occurrence of migraine headache.
Tryptophan: An essential amino acid and a natural precursor of serotonin
(Guyton, 1987). Brain tryptophan and serotonin decline after a protein-rich meal.
The large neutral amino acids compete for access to the same carrier molecules for
transport across the blood-brain barrier. And the brain influx of tryptophan declines
relative to its competitors after a high-protein meal. A meal rich in carbohydrates
increases brain tryptophan and serotonin synthesis (Wurtman, 1979).
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Theoretical Model of a Migraine Attack Episode
Introduction
From the theoretical model of the pathway for triggering migraine headache,
increased platelet aggregability is the key factor for triggering migraine headache
attack (see Figure 1.). The occurrence of increased platelet aggregability may be
caused by high levels of free fatty acids in the blood.
When platelet aggregation occurs, an action occurs which has been found to
cause vasodilatation. It is a fall in the plasma, platelets and CSF (cerebrospinal
fluid) serotonin level. The vasodilatation which occurs leads to migraine headache.
The model shows that low levels of serotonin may be overcome not only by
preventing an increase in free fatty acids in blood by following a low fat diet, but
also through a higher intake of tryptophan and higher intakes of vitamin B6 (both
are in complex carbohydrate) in the diet.
Based on recent literature, high blood levels of free fatty acids occur during a
migraine headache (Anthony, 1975). These high levels of free fatty acids are
biochemically associated with blood lipids. Elevated levels of blood lipids are often
caused by high dietary fat intake and by other diseases in which an accumulation of
fat or disruptive competitive metabolism between fat and carbohydrates develops,
such as obesity or insulin resistance (Groop, 1991; Widen, 1992). Other states which
can increase the levels or change the ratios of blood lipids, trigger high levels of free
fatty acids or increase platelet aggregability are: vigorous exhaustive exercise,
hunger, alcohol or coffee and caffeinated drink consumption, oral contraceptives
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with high estrogenic activity, smoking and stress (Fried, 1992; Curatolo, 1983;
Raskin, 1988; Thompson, 1987). The effect of coffee has been demonstrated to
increase plasma free fatty acids by 50-100 percent (Curatolo et al., 1983). Attacks of
migraine have been reported in patients with some platelet disorders such as
thrombocytopenia (Davidoff, 1995). The increased platelet aggregability causes the
release of serotonin from platelets and producing low levels of serotonin in platelets.
The rapid degradation of this released serotonin reduces the level in the plasma and
CSF as well. Migraine headache was recently called a low plasma serotonin
syndrome (Anthony et al., 1975). Released serotonin from platelets is degraded
immediately by mono-aminoxidase (MAO) to the urine metabolite
5-hydroxyindoleacetic acid, the level of which is highly elevated in urine during a
migraine attack. Intravenous administration of serotonin itself has been shown to
relieve the migraine headache (Davidoff, 1995). The effect of serotonin on blood
vessels is vasoconstrictive, and therefore with a decrease in serotonin, vasodilatation
predominates, which it is believed causes the pain of a migraine headache.
Levels of neurotransmitters in the platelets are suggested to reflect those in
the nervous system (Nakano et al., 1993). It can be assumed that if there is a low
level of serotonin peripherally, there will likely be a low level of serotonin centrally.
The precursor for prostaglandins (PG1) is linoleic fatty acid, the most
common essential fatty acid in the human diet (Peatfield et al., 1981). It is possible
that due to high dietary fat intake, there is also increased intake of the precursors of
prostaglandins. Prostaglandins in high concentration cause vasodilatation.
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Connections of Factors in Triggering Migraine Headache
A high dietary fat intake, or other states described above which are capable
of increasing blood lipids or free fatty acids, can cause platelet aggregation, an
indirect factor in the vasodilatation which precedes a migraine headache. High
levels of dietary linoleic fatty acid intake can produce an increased level of
prostaglandins which take part in the vasodilatation process and migraine
headache. Intake of oral contraceptives (especially those with higher levels of
estrogen) can cause platelet aggregation and lead to vasodilatation followed by
migraine headache.
Conclusion
The proposed model of migraine headache, from left to right (Figure 1.1), is
explained as follows:
High dietary fat intake (and other factors such as obesity, insulin resistance,
vigorous exhaustive exercise, hunger, alcohol, coffee and other caffeinated
beverages, oral contraceptives with high estrogenic activity, smoking and stress) can
produce high levels of free fatty acids and an increase in blood lipids. The increase of
free fatty acids then creates platelet aggregability. The increased aggregation of
platelets is followed by adverse changes in the amount of serotonin and
prostaglandins. Serotonin can also be independently influenced by changes in the
amount of dietary vitamin B6 and tryptophan. Furthermore, prostaglandins can be
influenced by changes in the levels of linoleic acid which is a component of high
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dietary fat intake. These changes in serotonin and prostaglandins may cause the
vasodilatation leading to a migraine headache.
The key symptom which occurs in migraine headache is vasodilatation. The
key action that precedes vasodilatation is increased platelet aggregation and platelet
destruction. The known cause of platelet destruction is a high levels of free fatty
acids. The obvious factor that can cause high levels of free fatty acids and high levels
of blood lipids is high dietary fat intake - thus this may be the key etiologic key
factor in causing migraine. The destructive effect on platelets by a high dietary fat
intake can be modified by reducing dietary fat intake.
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Figure 1.1 Theoretical model of migraine attack episode

Vasodilatation & Migraine Headache
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CHAPTER 2
IN SEARCH OF THE IDEAL TREATMENT FOR MIGRAINE HEADACHE
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Abstract
Migraine headache is a common syndrome afflicting millions of Americans
that has so far defied a definitive cure. Experimental research studies of the
syndrome tend to describe the triggering factors separately. We propose a common
denominator, namely, high levels of blood lipids and free fatty acids, as underlying
factors in the development of migraine headaches. Biological states that may
cause increases in free fatty acids and blood lipids include: high dietary fat intake,
obesity, insulin resistance, vigorous exercise, hunger, consumption of alcohol,
coffee and other caffeinated beverages, oral contraceptives, smoking and stress.
Elevated blood lipids and free fatty acids are associated with increased platelet
aggregability, decreased serotonin, and heightened prostaglandin levels. These
changes lead to the vasodilatation that precedes migraine headache. We suggest
that migraine headache should not be seen as an isolated symptom, but as a first

18

signal of potential biochemical imbalances in the body, which can lead to
development of chronic disease.
Introduction
Migraine headaches are a common and painful experience for many young
American adults. They are two-and-a-half times more prevalent in women,
occurring in 6 percent of all males and 15-17 percent of females (1). It is more
likely to strike those aged 25 - 44 (2). with 90 percent of migraine patients
reporting their first attack before age 40 (2,3). The functional impairment of
patients with chronic headache disorders is comparable to that of patients with
active cardiac disease, such as myocardial infarction or congestive heart failure
(4).
Medical literature describing migraine headaches tends to concentrate on
symptomatic relief rather than elucidating the causes of migraine. For example,
Lance (5), in a recent review of migraine headache treatment, suggests a
management strategy that concentrates only on symptomatic relief
(pharmacological agents and even surgical intervention), without fully addressing
the causes of migraine. This calls to mind a comment by the late Norman Cousins
(6) who maintained that one of the most ignored facts about pain is that it is best
treated by eliminating the underlying cause. Pain, in our opinion, should thus be
viewed as a warning signal and not be immediately masked or medicated before
finding its source.
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Hypotheses
We hypothesize a common denominator in the pathophysiology of migraine
headache, namely high levels of free fatty acids and blood lipids, which if
eliminated, will markedly improve the quality of life of migraine headache
sufferers. We further suggest that migraine headache may be the initial signal of
biochemical imbalance in the body, which should be treated, not only to alleviate
the headache itself, but other possible complications. Unfortunately current
treatment is focused only on symptomatic relief, using vasoconstricting drugs to
counter vasodilatation and other pharmacological methods to elevate serotonin.
We propose that the common denominator for the development of migraine
headache (high levels of blood lipids) is similar to that for development of
cardiovascular disease, diabetes, stroke, and obesity. We further hypothesize that
the occurrence of migraine headache in young adults (up to age 45) may be an
early warning signal for the development of chronic diseases later in life. In view
of this we suggest that a low fat diet, stress management, and a healthy lifestyle
(no smoking, alcohol or caffeine) will combine to decrease body fat and will thus
curtail the occurrence of both present migraine headaches and future chronic
disease.
Theory on the Mechanism in Migraine Headache
There are two theories regarding the mechanism of migraine headache,
which involve vasodilatation (7). The vascular origin theory proposes that initial
vasoconstriction of the intracranial vessels reduces blood flow, resulting in
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cerebral hypoxia that in turn triggers vasodilatation of the cranial circulation.
This process stretches the sensitive nerve endings in the vascular walls giving rise
to migraine head pain (8,7). The second explanation emphasizes that migraine
headache is initiated by low levels of brain neurotransmitters, such as serotonin.
Serotonin depletion produces vasodilatation and also influences the level of other
neurotransmitters involved in triggering migraine headache (7).
High dietary fat intake, obesity, insulin resistance, vigorous exercise,
hunger, alcohol, caffeinated beverages, oral contraceptives with high estrogen
activity, stress and smoking, identified as factors involved in migraine headache,
all share the common denominator of an increase in blood lipids and free fatty
acids. Below is a description of the pathway from increased blood lipids and free
fatty acids to vasodilatation and the experience of migraine headache.
[Place Figure 1 approximately here]
Platelets may be considered as biochemical storehouses containing a
number of enzymes and substances capable of triggering migraine headache
(especially serotonin) (9). When platelet aggregability is increased platelets are
destroyed and the levels of stored platelet components decreased. Changes in
these platelet components can lead to vasodilatation (10). Thus increased platelet
aggregability can contribute to the development and severity of migraine
headache and inhibition of platelet aggregation is considered of therapeutic value
in migraine headache. Platelet aggregability, damage, and adherence to vessel
walls have all been shown to be promoted by free fatty acids (11). The increased

21

presence of lipid fractions has been shown to facilitate blood clotting in vitro, and
hypercoagulability has been demonstrated in blood taken from human subjects
after a meal of high fat content (11,12). Certain free fatty acids (FFA) such as
stearic, linoleic, oleic, and palmitic acids are elevated above normal levels during a
migraine attack [stearic (36%), palmitic (80.3%), oleic (95%), and linoleic
(137.5%)] (13).
Glueck and Bates found a connection between juvenile migraine and high
blood lipids (14). Tauber and others speculate that high levels of LDL cholesterol
might be etiologically involved in migraine headache, possibly through the
mechanism of endothelia cell injury (15). It has been demonstrated that platelets
display hyperaggregability in the presence of elevated LDL cholesterol both in
vitro and in vivo (16). That antiyperlipidemic drugs are also helpful in the
treatment of migraine headache supports a connection and similar etiology for
migraine headache and cardiovascular disease. Clofibrate, for example, is effective
in reducing both serum cholesterol and triglyceride concentration, but it also
reduces platelet adhesiveness (aggregability) and decreases the occurrence of
migraine headache (17). A clinical trial on low dose of aspirin (81 mg/day) reports
reduction of frequency, severity and duration of migraine headache after 3-4
months. Aspirin is known to have antiplatelet effect (prevents platelet
aggregability) (18).
Finally, the increased levels of prostaglandins also lead to vasodilatation.
The amount of prostaglandins is directly affected by high dietary fat intake
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through the high intake of linoleic acid, which is the precursor for prostaglandins
(19).
The Immediate Precursors of Vasodilatation
Below is a discussion of the factors that lead to vasodilatation.
Serotonin: Migraine headache has been described as a low serotonin
syndrome (20). In a study of serotonin and migraine headache by Lance et al. (21)
the mean plasma serotonin was 0.72 units in the headache free period, 0.82 units
in the 24 hours preceding a migraine headache, 0.45 units during a migraine
attack and 0.71 units during the 24 hours immediately following a migraine
headache. Experimental intramuscular injection of reserpine, which initiates the
release of serotonin, produced the lowest plasma serotonin level within 7 to 48
hours after injection with some changes occurring in as little as three hours.
Migraine headache was induced in all cases, indicating that low levels of serotonin
trigger migraine (21). During migraine headache, serotonin is released from
platelets and rapidly degraded by mono-amino-oxidase to 5-hydroxyindole acetic
acid (5 HIAA) and excreted in the urine, causing low levels of plasma serotonin
(20).
Plasma serotonin levels decrease during increased platelet aggregation
leading to vasodilatation with accompanying migraine headache. Free fatty acids
such as stearic, palmetic, oleic, linoleic and behenic are potent releasers of platelet
serotonin in vitro (22). Anthony and others reported that plasma free fatty acids
rose and platelet serotonin content fell during migraine episodes (13, 19, 23).
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Leviton et al. (17) found an almost total cessation of migraine attacks
following therapy that reduced elevated serum lipids in two patients with Type IVhyperlipoproteinemia (hyper-pre-beta-lipoprotenemia). The authors concluded
that the platelet clumping that occurs with hyperlipidemia might result in release
of serotonin, initiating a migraine attack (17). Thus there is some evidence that
blood lipids and free fatty acids are linked to migraine via serotonin activity.
Plasma serotonin levels, which are low during migraine headaches, can be
increased not only by low fat diet that maintains platelet integrity but also by
increasing complex carbohydrate diet namely increases in dietary vitamin B6 and
tryptophan. Tryptophan is a precursor for serotonin and vitamin B6 takes part in
synthesis of serotonin. (24, 25). High intake of tryptophan accelerates serotonin
synthesis (26). A complex carbohydrate diet contains vitamin B6 and tryptophan
(27). Low level or deficiency of vitamin B6 decreases the concentration of enzyme
pyridoxal phosphate which takes an important place in synthesis of serotonin and
other neurotransmitters. When there is a low intake of vitamin B6, there may be
decreased production of serotonin (24). Levels of serotonin has been shown to rise
after a carbohydrate meal (26,27). Furthermore high levels of prostaglandins
(which precursor is linoleic acid), which cause vasodilatation, can be directly
influenced by low fat diet, that follows with low amount of linoleic acid.
Prostaglandins: Foods high in fat are also high in linoleic acid, a precursor
of prostaglandins. Prostaglandin El (PGE1) is one of the most powerful known
vasodilators. It depresses smooth muscle contraction in resistance vessels during
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intravenous infusion, causing headache (28). A high fat diet induces platelet
aggregability, which in turn releases platelet serotonin temporarily elevating
plasma serotonin levels. Prostaglandin synthesis in blood vessel walls is also
stimulated by serotonin (28). The elevated serotonin stimulates the production of
prostaglandins which have a potential vasodilatating effect resulting in migraine
headache (19,29).
Other possible factors: Changes in levels of substance Fj histamine, taurine,
leucotriens, magnesium, endorphins, calcium, vitamin D and others, whose
changes were described during migraine headache, can trigger the chain of
different reactions leading to vasodilatation, increase of extravascular
permeability or neurogenic inflammation and therefore to migraine headache.
(30,31,32,33,34,35,36,37,38,7). Some changes in levels of these other components
can occur as a response to the body's attempts to balance the damaged biochemical
environment during migraine headache.
A major function of serotonin is vasoconstriction. If serotonin is released
from platelets and plasma serotonin levels are increased then initially there is
vasoconstriction. But serotonin in plasma is very quickly degraded by monoamineoxidase (MAO), therefore the net result of platelet aggregation is a decrease in
plasma serotonin and the resultant vasodilatation.
Factors Contributing Indirectly to Vasodilatation
High dietary fat intake: John Fothegrill, an eminent British physician of
the eighteenth century, commented in his 1784 treatise on the subject of
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headaches (39) that "There are some things which, in very small quantities,
seldom fail to produce the sick headache in some constitutions. Such are a larger
portion than usual of melted butter, fat meats and spices, especially common black
pepper. Meat pies often contain these things united and are as fertile a cause of
this complaint as anything I know; so are rich baked puddings and everything in
similar nature (40)”. This is apparently the first documented connection between
dietary fat and migraine headache.
Many patients report that their migraine attacks occur following the
ingestion of fatty meals (19). In a study of Australians, fats, fried foods and
chocolate were often identified "as provocative factors" for migraine headache (41).
McCarreen et al. (42) found that substituting dietary omega-3 fatty acids for
omega-6 fatty acids in adults significantly reduced migraine frequency and
intensity and formed the basis for the hypothesis of the pathophysiologic
association of dyslipoproteinemias with migraine. Diets rich in saturated fat and
poor in omega-3 fatty acids elevate low density lipoprotein lipids levels, and also
elevate prostaglandin PG1, a potent vasodilator. Diets rich in saturated fats may
be partially responsible for elevated low density lipoproteins and may be
associated with increased platelet aggregability (14,43,). Medina and Diamond
(44) reported no effect of diet on migraine headache, however the food groups
chosen were not categorized by amount of total fat, but rather by high or low
levels of tyramin. If it is dietary fat that is critical to the frequency and intensity
of migraine attacks then Medina and Diamond's (44) findings are not surprising
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cince similar levels of total fat were found in each their experimental diet groups.
Obesity: Increased flux of free fatty acids from abdominally localized
adipose tissue in obesity is considered a precursor for migraine headache (45, 46).
Obesity is characterized by enlarged fat mass, which in turn is positively
correlated with plasma free fatty acids concentration (47). Obese patients are
more likely to have hypertriglyceridemia (48), and visceral fat loss is associated
with improvements of serum lipid profile (49). A low fat diet combined with
weight loss can decrease serum lipids and free fatty acids leading to a decrease in
platelet aggregability, which reduce the immediate precursors to vasodilatation
and migraine headache.
Insulin resistance: Insulin resistance induces the increase in plasma free
fatty acids. (48,50). A high level of triglycerides (hypertriglyceridemia) is seen
frequently in NIDDM (51). Triglycerides, as a part of the blood lipids, may be
involved in platelet aggregability leading to vasodilatation and migraine.
Vigorous exhausting exercise: Thompson (52) reported that strenuous
vigorous exercise triggers migraine headache. During extended vigorous exercise
fatty acid metabolism increases. Migraine headache may occur after any type of
exhausting muscular effort such as tennis, wrestling and other sports (53, 54),
producing a corresponding increase in the plasma free fatty acids, leading to an
increase platelet aggregability followed by vasodilatation and the occurrence of
migraine headache.
Hunger: Migraine headache has been reported in cases of prolonged
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hunger (7, 55). During hunger or starvation the fatty acid metabolism is increased
and higher levels of free fatty acids in blood lead to an increase in platelet
aggregability This increased platelet aggregability may lead to changes in the
amount of serotonin as discussed earlier.
Alcohol: Migraine headache has been reported after ingestion of alcohol (7).
Alcohol is a non-specific vasodilator, which may account for its precipitation of the
vascular process in migraine headache (56). Migraine headache after ingestion of
large quantities of alcohol may be caused by increased levels of free fatty acids
which are a products of alcohol degradation (55).
Coffee and other caffeinated beverages: Fennely et al. (57) focused on the
connection between coffee and migraine found that with each 100 mg increase of
caffeine consumption there was a 12 percent increase in the odds of migraine
headache. This appears to be due to an increase of both low-density lipoprotein
and high-density lipoprotein. Consumption of 720 mL/d (24 oz) of caffeinated
coffee also lead to a statistically significant increase in the plasma level of
cholesterol. A lipid-rich extract from boiled coffee (amount 900 m/L) caused a rise
of LDL cholesterol by 29-30% (58). Finally, caffeine increases plasma level of free
fatty acids by 50-100% (59).
Oral contraceptives with high estrogenic activity: Oral contraceptives
produce destructive changes, including platelet aggregability, in platelet behavior
(60). Combined oral contraceptives with a relatively large estrogenic activity
increases platelet aggregation (61). In patients without a migraine history,
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starting oral contraception, triggered migraine headache and produce changes in
platelet behavior similar to those found in non-treated migraine patients (62,63).
Smoking: Daily headaches are more common among patients who smoke
than among those who do not (64). One-third of migraine patients contend that
smoking initiates or exacerbates headache symptoms (65). Smoking increases
LDL-C, decreases HDL and also causes an increase in the number of red blood
cells. Platelet aggregability is also increased in smokers (66).
Stress: Stress is often associated with the fight and flight response, when
free fatty acids are increased (55). If a person experiences continuous stress the
accumulation of lipids follows. This elevation is consistent with a chronic stress
reaction and the accompanying heightened sympathetic activity (67). Increases in
cholesterol, triglycerides, LDL cholesterol and HDL cholesterol levels are
mediated by stress (68).
Conclusions
In this paper we summarize the evidence for a common denominator of migraine
headache: elevated lipid levels and free fatty acids. Several things can produce
high levels of free fatty acids and an increase in blood lipid levels: high dietary fat
intake, obesity, insulin resistance, vigorous exercise, hunger, consumption of
alcohol, coffee and other caffeinated beverages, oral contraceptives with high
estrogenic activity, smoking and stress. The increase of free fatty acids creates
platelet aggregability, which leads to a variety of biochemical precursors to
vasodilatation, specifically decreased plasma serotonin. The direct effect of high
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dietary fat intake is in increased levels of prostaglandins. These changes cause
vasodilatation which leads directly to migraine headache.
Treatment for reducing the risk of cardiovascular disease, decreasing high
blood lipid levels, insulin resistance and obesity can be non-pharmacological and
usually consists of a low fat, low cholesterol diet and an exercise program (43,69).
If similar etiologic mechanisms (such as high levels of blood lipids and free fatty
acids) exist in both cardiovascular disease and migraine headache, it is logical to
also recommend a low fat diet to migraine patients (43). A low fat diet may
prevent the occurrence of high free fatty acids and high blood lipids and therefore
prevent platelet destruction and subsequent changes in serotonin. A low fat diet
may also decrease consumption of linoleic acid, a precursor for prostaglandins,
and therefore decrease synthesis of prostaglandins. In addition, dietary
modification that includes an increase in the consumption of complex
carbohydrates can increases serotonin levels which may in turn alter the
pathophysiological pathway to migraine headache.
The "magic cure for headache" may be to minimize factors discussed above
by changing lifestyle. Suggestions include: consuming a low fat diet, increasing
the intake of complex carbohydrates, getting moderate not vigorous exercise, not
skipping meals or experience prolonged hunger, quitting smoking, decreasing
consumption of alcohol, coffee and caffeinated beverages and decreasing stress by
relaxation techniques. While there may be no ideal treatment for migraine
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Figure 2.1 Theoretical model of migraine attack episode
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CHAPTER 3
METHODS
Setting and Subject Selection
Setting
The study drew subjects from two locations. One location was the Family
Medicine Practice in Irvine, the second was at the office of Center for Health
Promotion and Education at Loma Linda University The choice of these two
locations was made for the purpose of recruiting more participants, and
availability of the offices for conducting the study. All of the investigation and
intervention procedures were conducted by the primary investigator. Two nurses
completed the initial intake during administrative procedures at both sites. The
study began in March 1994 and continued until the final participant completed
the study in October 1994. The study was based on a staggered continuous
enrollment. Subjects did not know each other, and so it is reasonable to assume
that they made no contact with each other during the study. There was no
separate control group, since each subject served as his/her own control. Dietary
intervention was provided on an individual basis. Emphasis was placed on
preventing baseline patients from having appointments on the same day as
subjects in the post-intervention period in order to prevent cross-communication.
Recruitment
The advertisement used for recruiting was placed in local newspapers, local
medical offices, hospitals and other local community centers (Appendix A). Twelve
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of the subjects were referred by the Family Medicine Practice in Irvine, one of the
intervention sites. A total of 98 subjects expressed interest in participating in the
study. An initial Phone Screening Interview was conducted with each of the
potential participants (Appendix B). If the subject was eligible according to the
Phone Screening Interview, the Intake Interview (Appendix C) was mailed to them
or given to them at the introductory meeting. An Informed Consent, approved by
the Loma Linda University Institutional Review Board, was signed by each
participant before beginning the study (Appendix D). During the initial meeting
subjects were informed of the importance of keeping food, headache, and medication
diaries for the four baseline weeks. They were then advised that according to their
records (diaries) an appropriate individualized intervention would be designed.
Subjects were informed that no supplements or drugs would be used and that the
study would be based only on a lifestyle intervention diet, similar to diets already
recommended for many types of chronic diseases.
Inclusion Criteria and Procedures
Inclusion Criteria
The decision for including participants in the migraine study was based on
the Phone Screening Interview (Appendix B) and the Intake Interview (Appendix
C). The Intake Interview was sent by mail or given during the introductory
meeting, and collected before the study started. Subjects had to fulfill all the
following requirements (inclusion criteria) in order to be accepted into the study.
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Subjects must:
1. Not have been on any diet within the 3 months prior to the study. This
might influence the cluiracteristics of headaches during the baseline period.
Subjects already following a diet of their own were excluded.
2. Be older than 20 years. People younger than 20 years have different
Recommended Dietary Allowances (RDA) on dietary intake (RDA, 1989). It is
assumed that dietary restrictions may interfere with the growing process of a
younger population. Also other studies (Stang, 1993; Post, 1986) show that migraine
headaches primarily afflict those over 25 years of age.
3. Have a migraine headache at least once a month. If headaches occur less
than once a month, it is difficult to detect headaches and compare them between
baseline and intervention periods.
4. Have a history of headache for at least one year. It was assumed that if the
headache history was less than one year, migraine headache may not have been
diagnosed at all, diagnosed accurately or may have unknown etiology. The subject
was considered to be in the stage of developing diagnosis and finding the causes of
headache.
5. Be diagnosed with migraine headache (with aura or without aura) or
fulfilled requirements according to International Headache Classification of
migraine-headache (IHS, 1988; Olesen, 1989). Subjects taken into the study had
been diagnosed and classified as migraine patients by their physician. Each subject
was reevaluated and the diagnosis compared to the International Classification for
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diagnosis of migraine headache with aura and without aura (IHS, 1988; Olesen,
1989). Only those meeting these criteria were included.
6. Have no headache in connection to a head injury or organicity. These
subjects were excluded from the study because of the possibility of a different origin
for these headaches. These headaches may not respond to dietary intervention due
to the distinctive nature of the condition.
7. Be a non-smoker. Smoking may influence lipid profile and trigger
headache (Davidoff, 1995). Volans et al. (1976) found that smoking can initiate or
exacerbate headache symptoms. Thus only non-smokers were included.
8. Have no pregnancies beyond the first trimester. Pregnancy can alter the
pattern of established migraine headache. Migraine cases may improve during
pregnancy, especially during the second and third trimester due to hormonal
changes (Callaghan, 1968). Also, according to Recommended Dietaiy Allowances
(RDA), it would not be appropriate to significantly alter diet among pregnant
women (RDA, 1989).
9. Have no diabetes. Because diabetics are often already on a restricted diet,
an intervention to significantly reduce dietary fat would not be appropriate.
Diabetics were excluded.
10. Do not experience only tension or cluster type of headache. Tension or
cluster type headaches have different characteristics, and also a different type of
etiology, than migraine headaches (IHS, 1988; Olesen, 1989). Therefore, the
occurrence and frequency of tension or cluster type headaches follow a different
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pattern than the migraine headache and may respond differently to dietary
intervention. Subjects with a combination of headaches such as migraine with
tension or cluster type: headaches, however, were allowed to remain in the study,
because of also having migraine headache.
11. Have had hormonal treatment for more than one year. Starting hormonal
treatment or changes between different types of hormonal therapy may trigger
migraine headaches (Davidoff, 1989). Subjects undergoing hormonal treatment,
including use of oral contraceptives and estrogen replacement, were allowed to
participate if they had been using the hormonal treatment for at least one year. This
was based on the assumption that during this one year period the subject would
have found a stable level and type of hormonal treatment. Subjects who planned to
start or stop the hormonal treatment during the study were also excluded.
Procedures
All patients who responded to the advertisement and fulfilled criteria for
subject characteristics were included in the study. Recruitment started on January
1994 and continued until July 1994. The study began on March 1994 and ended in
October 1994 (Figure 2.). Each subject completed the full 12 weeks of the study. The
study consisted of a four week baseline period followed by eight weeks of dietary
intervention. The eight weeks of dietary intervention was divided into two blocks,
each consisting of four weeks. When each block was finished, subjects were
evaluated and diaries were collected (Figure 3.). The study was completed in
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October 1994, the month when the last patient finished the required 12 week period
(Figure 2.).
Data Collection
The medical history, headache history, and other demographic data was
collected from the Phone Screening Interview and from the Intake Interview
(Appendices B, C). Both interviews and Informed Consent (Appendix D) were
conducted before subjects were enrolled into the study (Figure 3). In each medical
office at the end of the four week baseline period the following data were collected
from subjects: Perceived Stress Scale, Physical Activity Questionnaire, Headache
Profile, Food Diaries (Appendices E, F, G, H) and the following anthropometric
measurements were performed: weight, height, 7-site skinfolds measurements
(Appendix I).
The one-on-one intervention (1 -1.5 hours) was then provided to each
subject. After the inteivention, an eight week period of low fat diet followed, broken
into two four weeks blocks. At the end of the first four week post-intervention
period, the following data were collected from subjects: Headache Profile and Food
Diaries (Appendices G, H). In each medical office, the following anthropometric
measurements were performed: weight and seven-site skinfolds measurements
(Appendix I). A discussion of subjects' questions and support for maintaining low fat
diet occurred for 1-1.5 hours. This was followed by another four week period of low
fat diet. At the end of the study (the entire four week baseline and eight week
intervention period), the following data were collected: Perceived Stress Scale,
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Physical Activity Questionnaire, Headache Profile and Food Diaries (Appendices E,
F, G, H). In each medical office, the following anthropometric measurements were
performed: weight, and the seven-site skinfolds measurements (Appendix I). For
non-randomly selected 12 subjects a blood test was administered (Appendix J) and
blood records from their medical charts before the study were gathered. The blood
test was administered only to subjects who wanted the test and who were able to
pay for it. Finally progress notes that assessed subject's subjective evaluation of the
intervention and headache outcome were also administered and collected (Appendix
K).
Before and during the study subjects were encouraged to send their diaries
to the investigator every 10 days. According to this system, it was possible to notify
patients or to remind them to send and keep diaries, in case a record was not
received. This was a good technique for maintaining patient compliance in writing
diaries and continued recording.
Instruments
1. Demographic and medical assessment: Phone Screening Interview,
Intake Interview.
To collect demographic information about patients, the Phone Screening Interview
was administered during the first contact with the potential participant (Appendix
B). The Phone Screening Interview assessed the medical histoiy of patient's
headache, characteristics of headache, usage of medication, and required
characteristics for intake into the study. Diagnosis of migraine headache was
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confirmed using the Headache Classification from the International Headache
Society (IHS, 1988; Olesen 1989). After the first contact with the potential
participant, the Intake Interview was administered to the selected participants
(Appendix C). The Intake Interview collected a more detailed medical history,
headache characteristics, triggers of headache, dietary habits and overall lifestyle
habits.
2. Stress assessment: Perceived Stress Scale.
For measuring stress, the Perceived Stress Scale by Cohen, Kamarck, &
Mermelstein (1983) was used (Appendix E). Patients were instructed to answer the
questionnaire on stress at the beginning (baseline) and at the end of the study (after
the eight week intervention period).
3. Physical activity assessment: Physical Activity Questionnaire.
Physical activity was assessed using the physical activity questionnaire section from
the Nutrition Profile Plus, this questionnaire was developed by Wellsource Inc. of
Clackamas, Oregon, 1987 (Appendix F). Subjects were instructed to complete the
forms at the beginning of the study (baseline) and at the end of the study (eighth
week of the intervention period).
4. Migraine headache and drug intake assessment: Headache Profile.
The Headache Profile shows how headache diaries, headache rating scale, and
medication monitoring were used (Appendix G). The evaluation of the headaches
followed the steps described in a study by Blanchard (1985). The study provides a
verbal description to each of the six points (0 through 5) which are used as the
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headache rating scale in the present migraine study. The headache diary sheet for
the present study was adopted from Blanchard (1985). The system was modified in
that the headache record in the present study involves a 24 hour report about the
headache (occurrence, changes in intensity and termination of headache were
registered). During the headache, subjects were asked to record any medication they
took for headache control and relief each day. Subjects were asked to keep records
on how many times medication was taken and when it was taken (Appendix G).
Medication records followed the procedure recommended by Blanchard (1985).
5. Dietary assessment: Food Diaries.
The "24-hour recall form" (NRC - National Research Council, 1986) was used to
record subject's food intake for entire 12 week study period (Appendix H). Subjects
were instructed to record their food diaries immediately upon eating or once a day
following the evening meal. Instructions were given on how to keep records and
assess portions (using standard household measuring cups, spoons, slices, counts
etc.). It was emphasized that each patient must record everything that they
"swallowed" including water and vitamin supplements and medication. The
precision of the "24-hour recall" (record) has been examined when used to estimate
the mean nutrient intake, and results based on paired t-tests and/or correlation
analysis have suggested that this method can provide a relatively precise estimate of
food intake (Rasanen, 1979).
6. Anthropometric assessment: weight, height, 7-skin folds measurements.
Weight was assessed using a standardized technique and balance beam scale.
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Subjects always came for afternoon measurements for consistency. Subjects were
measured without shoes and in light dress each time (Nieman, 1990). Height was
assessed using a standardized technique (Nieman, 1990). The instruments used
were from medical offices where the measurements were performed. For 7-skin fold
measurement (body fat) a Harpenden caliper from the Exercise Physiology
Laboratory from Loma Linda University was used, following the standardized
technique for body fat assessment (Nieman, 1990).
7. Blood Lipids Assessment: Present blood test and blood test record.
Present blood test was taken by standardized procedure (Clinical Laboratory Tests,
1991) from 12 subjects at the end of the study at the Family Medicine Office by
registered nurse and w<is sent to a standardized laboratory (National Health
Laboratories) for evaluation. For these 12 subjects, the blood test record from
standardized laboratories was taken from subject's medical charts any time before
the beginning of the study.
8. Satisfaction Assessment: Progress Notes.
At the end of the study subjects received the Progress Notes (questionnaire) that
assessed their perceptions of the quality of the intervention and impact of dietary
changes on their migraine headache (Appendix K).
Dietary Fat Intervention Protocol
The intervention was 1-1.5 hours and was delivered after each subject
completed the baseline period. Materials with detailed explanations were given to
subjects (Appendix L) at this time that included instructions on eating a low fat
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diet (20 grams/ day) with suggestions and examples of low fat menus from the
book "T-Factor: One Meal at a Time" by Katahn (1991). The books "T-Factor" by
Katahn et al. (1991) and "Diabetes - Exchange List" by Anderson (1983) were
given to every subject so that they would be aware of high fat foods to avoid. The
book "Cooking Without Fat" by G. Mateljan (1992) was also given to subjects along
with sample foods (e.g., non-fat granola bars and other non-fat products) from the
Healthy Valley Foods company, which supported the research by providing free
cookbooks and samples of food for each participant. Subjects were instructed to
decrease their intake of fat to 20 grams or less per day. The intervention
consultation was provided on the individual basis for each subject. The subjects'
baseline food diaries were used during the intervention discussion to encourage
them to change eating habits and decrease their daily intake of fat. Suggestions
also involved increasing fruit, vegetable, and legume consumption in order to
combat hunger and cravings. Emphasis was also made on lowering coffee intake
and on increasing intake of water versus caffeinated beverages. After the first four
week block of low fat diet, each subject was again seen by the investigator and
time was spent in explaining and answering subjects' questions about low fat
foods, changing their eating habits to the low fat menu, and giving additional
advice and support on monitoring a low fat intake. This second session lasted
about 1-1.5 hour. A reminder phone call was made to the subjects every 10 days, if
subjects' diaries were not received, to encourage them to keep diaries, provide
support and discuss any questions they had.
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Data Analysis
The study design used a quasi-experiment with each subject receiving the
intervention after a four week baseline. The independent variable was the
intervention to reduce dietary fat intake. Dependent variables included: headache
profile (migraine headache-intensity, duration, frequency and times taken
medication); Perceived Stress Scale; anthropometric assessment-percent body fat
and weight; physical activity assessment and blood test for 12 of 54 subjects.
Sample Size
With a sample size of 54 and an alpha of 0.05 there was an 80% power to
detect a change of a 0.4 standard deviation in the number of headaches over a four
week period.
Modifications Upon Entering Data
Some patients were missing information on date of birth. If the date was
missing (but the year was there) July 1st and their year was used. Data were
analyzed using SAS (version 6.09), (SAS - Statistical Analysis System, Cary, NC).
Selection of Food Diaries for Analysis
The food diaries were analyzed with the Right Byte Program (the adaptation
of the Nutritionist III Program, 1987). Food diaries were analyzed on seven
randomly selected days during the first 28 day baseline and then the same sequence
of seven days was analyzed for the final 28 days of the study providing a total of 14
days. The midterm 28 days were classified as a transition period and were not
included in the dietary analysis.
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Dependent Variables
Migraine headache was determined by assessing days with headache, free
days from headache, numbers of headaches, single peak and headache index and
times taken medication for each subject. The single peak headache is the highest
score on the rating scale during each week for the 12 week period. For directions to
calculate the headache index instructions from Psychological Management of
Chronic Headache by Blanchard and Andrasik (1985) were used. Collected data
from 7-skin fold measurements were analyzed by computer program for the percent
of body fat. For the calculation of percent body fat the program from Loma Linda
University Health Promotion and Education was used. The program was developed
by D. Nieman - On the Loma Linda University ACSM Workshop Skinfolds
Calculation Program. The program calculates body fat percentage using the
7,6,4,3,3- site calculations for men and the 7,5,3,3,3-site calculation for women, as
listed on page 101 of the Sports Medicine Fitness Course (Nieman, 1990).
Statistical Analysis
The research design was a one-group pretest-posttest design 01x02. The
standard null hypothesis was that there would be no change in number of
headaches from baseline to post-intervention. The alternative hypothesis was that
there would be a significant reduction in the number, severity and duration of the
headaches from baseline to post-intervention. The non-parametric Wilcoxon Signed
Rank test comparing baseline to post-intervention period was used (Bailey, 1991).
The test determines the significance of the difference between pre-test and post-test
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scores for a quasi-experiment. For correlation analysis the non-parametric
Spearman Correlation Coefficient was used (Bailey, 1991). Stepwise linear
regression was used in standard procedures according to Salahuddin et al. (1991).
1. The non-parametric Wilcoxon Signed Rank test (Bailey, 1991): The nonparametric Wilcoxon Signed Rank Test comparing differences between baseline and
the post-intervention period was used for analyzing migraine headache components;
analyzing food diaries; anthropometric assessment (percent body fat and weight);
stress assessment (Perceived Stress Scale); physical activity assessment; blood test;
and subjects' responses to the program.
2. The Spearman correlation coefficient (Bailey, 1991): The Spearman
correlation coefficient was used for analyzing the relationship between migraine
headache components with food diaries, anthropometric assessment (weight,
percent body fat), stress assessment (perceived stress scale), blood test, physical
activity and other demographic and medical history data.
3. Stepwise linear* regression (Salahuddin et al, 1991): Stepwise linear
regression was used for analyzing food diaries, migraine headache components,
specific dietary fat components, blood test and demographic characteristics.
4. Simple statistics (mean, median) (Bailey, 1991): Simple measures of
central tendency of mean and median were also used for evaluation migraine
headache components and describing the demographic data.
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Figure 3.2 Study timeline
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Figure 3.3 Data collection timeline
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CHAPTER 4
THE INFLUENCE OF LOW DIETARY FAT INTAKE ON INCIDENCE AND
SEVERITY OF MIGRAINE HEADACHE
Zuzana Bic, M. D., Dr. E H., Glen G. Blix, Dr E H., Helen P Hopp, Ph.D.,
Frances M. Leslie, Ph.D., Michael J. Schell, Ph.D.
Submitted for publication, New England Journal of Medicine, Februaiy 1997. (Appendix
N)
Abstract
Background: Migraine headaches are a common, debilitating syndrome
causing untold suffering and loss of productivity. A review of the literature
indicates that there are two primary factors involved in triggering these
headaches: high levels of blood lipids and high levels of free fatty acids. Under
these conditions platelet aggregability is increased, which is associated with
decreased serotonin and heightened prostaglandin levels. This leads to
vasodilation, the immediate precursor of migraine headache. A high fat diet is one
factor that may directly affect this process. This study was undertaken to evaluate
the impact of dietary fat intake on incidence and severity of migraine headache.
Methods: The study was conducted over a 12 week period on 54 previously
diagnosed migraine headache patients. During the first 28 days the study subjects
recorded all food consumption in a diet diary and maintained a headache diary. At
the conclusion of this 28 day baseline period subjects were individually counseled
to limit fat intake to no more than 20 grams per day. A 28 day run-in period was
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then allowed for adaptation to the low fat diet. Results are reported on the final
28 day post-intervention period.
Results: Subjects significantly decreased the ingestion of dietary fat in
grams between baseline (mean=65.9, p<.0001) and the post-intervention period
(mean = 27.8). The decreased dietary fat intervention was associated with
statistically significant decreases in headache frequency, intensity, duration, and
medication intake (all pc.OOOl). There was a significant positive correlation
between baseline dietary fat intake and headache frequency (r=.44, p=.02).
Conclusion: This study indicates that a low fat diet can reduce headache
frequency, intensity, duration and medication intake.
Key words: migraine headache, low dietary fat intake, free fatty acids,
blood lipids, platelet aggregability.

Migraine headache is defined as an idiopathic recurring headache disorder
with a lateralized, pulsating pain, sometimes associated with nausea and
vomiting. Migraines may occur with or without visual disturbances [1, 2]. It is
presently estimated that migraine headaches afflict some 10 million Americans
[33.

Current literature describes migraine headache as a low serotonin

syndrome [4]. An onset of the headache is associated with reduced serotonin
concentrations in the platelets, plasma and cerebral spinal fluid, a transient
presence of serotonin releasing factor in the plasma, a platelet serotonin release
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reaction, and an increased urinary secretion of the serotonin metabolite 5hydroxyindoleacetic acid [4,5].
Several studies have reported high platelet aggregability and
hyperlipidemia in connection with serotonin release from the platelets during a
migraine headache [4-9]. The mechanism of platelet serotonin release seems to
be due to a variety of factors including mechanical trauma, blood clotting factors,
and the concentration of various fatty acids [10]. Anthony [6] identified a
serotonin releasing factor with a molecular weight of less than 50,000 which
would correspond to certain free fatty acids. He reported that the overall levels of
free fatty acids rose by more than 10% in patients suffering from migraine
headaches. He further found a 36% elevation in stearic acid, a 80% rise in palmitic
acid, a 96% increase in oleic acid, and a 138% elevation of linoleic acid during
headache episodes [6].
Other blood lipids may also exacerbate the problem. High levels of low
density lipoprotein (LDL) cholesterol may be etiologically related to migraine
attacks [11-13]. Glueck and others have shown this to be true in juvenile
migraines [14]. The presence of certain lipid fractions has been shown to facilitate
blood clotting in vitro and preexisting migraine is worsened during idiopathic
thrombocytopenia, especially during the phase of active platelet destruction
[9,10,15,16]. Inhibition of platelet aggregation has been considered to be of
therapeutic value in preventing migraine headaches [17]. It thus appears that any
mechanism that decreases platelet aggregability through a reduction in blood
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lipids and plasma free fatty acids may minimize the onset and duration of
migraine attacks. A single-arm clinical trial of low dose aspirin (81 mg/day), which
is known to reduce or prevent platelet aggregability, resulted in a statistically
significant reduction of frequency, severity and duration of migraine headache
after 3-4 months [18].
Foods high in fat are also high in linoleic acid, a prostaglandin precursor.
Prostaglandin El (PGE1) is one of the most powerful vasodilatators [19].
Horrobin [19] showed that El depressed smooth muscle contraction in resistance
vessels during intravenous infusion, thus causing headache. A high fat diet
induces platelet aggregability, which in turn releases platelet serotonin
temporarily elevating plasma serotonin levels. Prostaglandin synthesis in blood
vessel walls is also stimulated by serotonin [19]. The resultant prostaglandin
production has a vasodilatating effect resulting in migraine headache [20,21].
It is commonly accepted that diets rich in saturated fat elevate plasma LDL
cholesterol levels which in turn increase platelet aggregation [22].
Hypercoagulability has; been demonstrated in blood taken from human subjects
following a high fat meal [10]. It is possible that an elevated lipid profile,
influenced by a high intake of dietary fat may be the initial step in causing the
platelet disturbance process that triggers migraine headaches.
Because a diet low in total fat can directly decrease blood lipids and free
fatty acids, this study was designed to introduce a low fat diet to subjects with a
previously diagnosed history of migraine headaches and then measure the
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influence of diet on the occurrence, severity and duration of subsequent
headaches.
Methods
Subjects
Subjects were recruited through advertisements placed in local
newspapers, medical offices, hospitals and community centers in the cities of
Loma Linda and Irvine, California. Of 98 who responded 21 did not meet the
eligibility criteria, 17 chose not to participate and 6 dropped out before completing
the study leaving a total of 54 subjects (12 male and 42 female) aged 24 to 71 years
with a median age of 41. In order to participate in the study, subjects were
required to be at least 20 years of age, have received a medical diagnosis of
migraine headache wit h a headache history of at least one headache each month
for at least one year, have no history of headache connected to head injury or
organic cause, be non smokers and not diabetic. Pregnant subjects were limited to
the first trimester at time of intervention. No subject indicated participation in
any type of weight reduction diet within the prior three months. At least one year
of prior use was required of subjects on hormonal replacement therapy or
contraceptives. Subjects experiencing only tension or cluster type headaches were
excluded unless they also had a migraine headache diagnosis.
Study Protocol
This study was designed using a one group pre-test, post-test protocol. The
study protocol was approved by the Institutional Review Board of Loma Linda
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University and each subject signed an informed consent prior to beginning the
study. A staggered continuous enrollment of subjects in the study began in March
of 1994 and the project continued until the final participant completed the
protocol in October of that year.
An initial baseline period of 28 days was followed by the intervention and a
28 day transition phase. The final 28 day period was used to evaluate the results
of the intervention. All eligible subjects were initially provided with headache and
diet diaries and asked to keep detailed records of food and medication intake as
well as headache occurrence, severity and duration throughout the 12 weeks of
the study.
Following the 28 day baseline data collection period, each subject was
individually instructed regarding the recommended dietary change for the
Intervention period. Subjects were requested to keep their dietary fat intake to 20
grams per day. They received individualized one-on-one nutritional counseling,
appropriate hand outs and other pertinent reading materials.
No caloric restriction was recommended and they were advised to counter any
perceived hunger by increasing their intake of fruit, vegetables and legumes in
their diet. Subjects were also advised to limit their intake of coffee and other
caffeinated beverages and drink water instead.
Baseline and Follow up Assessments
Percent body fat was determined at baseline and at four, eight and twelve
weeks using a standard seven site skinfold measurement [23]. The weight of each
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subject was determined at baseline and reassessed at four week intervals during
the study. Instruction was provided in food diary record keeping and assessment
of food portion size. Subjects were asked to complete their diaries at the end of
each day. The headache scale was used from Blanchard and Andrasik [24].
Subjects were given detailed instructions on how to record each headache episode
and the time, type, and amount of any medication used to combat the headache.
The intensity of pain was recorded on a 6 point rating scale (0-5), with 5 being
the most severe and 0 being no pain whatsoever. Subjects were instructed to use the
scale to report changes in the pain intensity level throughout the duration of the
headache. Finally at baseline and at the conclusion of the study subjects also
completed the Perceived Stress Scale [25] and the physical activity status section of
Nutrition Profile Plus [26].
Statistical Analysis
With a sample size of 54 and an alpha of 0.05 there is an 80 % power to
detect a change of a 0.4 standard deviation in the number of headaches over a four
week period. Data were analyzed using SAS (version 6.09) [27]. Food diaries were
analyzed on seven randomly selected days during the first 28 day baseline period
and the same sequence of seven days was analyzed for the final 28 days of the
study providing a total of 14 days. The sequence of selected days for baseline and
post-intervention periods was the same within each subject, but varied across
subjects. The midterm 28 days were classified as a transition period and were not
included in the dietary analysis. All diet records were analyzed for nutritional
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content using the Right Byte Computer program [28]. A log scale for headache
frequency was used to reduce positive skewness. Before taking the log, one was
added to all frequencies so that the log would exist. Differences in headache
measures, food diaries, weight, percent body fat, perceived stress and physical
activity between the baseline and post-intervention period were compared using
the Wilcoxon Signed Rank Test [29]. The reduced monotonic regression method
[30] was used to explore relationships between the dietary nutrient variables and
headache frequency. For this method Ri (the square root of Ri^ defined by
Kvalseth [31] ), a generalization of the Pearson correlation coefficient, was used to
assess the strength of the association. For all other correlation’s the Spearman
correlation coefficient (denoted r) was used.
Results
Demographics
The subjects who successfully completed the study (N=54) reported a
medical history of a greater frequency of migraine headache per week (median=2
vs. median=l, p=.05) and a longer history of migraine headache in years
(median=13 vs. median=10, p= .04) than the 6 dropouts. Of the 54 participants,
14 % were using contraceptives, 6 % were using hormonal replacement, and 11 %
were using prophylactic headache therapy. None of these characteristics showed
any significant relationship with migraine headache in this study. There were no
significant differences in the baseline headache frequency by age or by gender.
There was no significant difference in the perception of stress between the
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baseline and post-intervention period based on a comparison of scores (scale 0-4)
on the Perceived Stress Scale (median=0, p=.17). There was also no statistically
significant change in the reported hours of vigorous physical activity (median=0,
p=1.00).
Dietary Changes
Statistically significant decreases from baseline to the post-intervention
period occurred for all fat components (all p-values were <.0001): totsil fat (58%
decrease, from mean = 65.9 gm/day to mean=27.8 gm/day), polyunsaturated fat
(63% decrease), saturated fat (63% decrease), cholesterol (53% decrease), oleic
fatty acid (63% decrease) and linoleic fatty acid (74% decrease) [Figure 1.]. All 54
subjects had lower fat intakes at post-intervention compared to baseline. The
range of fat intake during baseline was 26 - 122 grams of fat per day and 9-75
grams per day at post-intervention. Smaller changes were seen in other nutrients
and a significant drop in caloric intake occurred [Figure 1.]. Reported dietary
changes from the food frequency questionnaire were corroborated by physical
measurements. First, there were statistically significant decreases in subjects'
weight (median = 2 lb., p=.0006) and percent of body fat (median = 4.2 %,
p<.0001) between baseline and post-intervention [Table 1]. Second, blood draws
on a subset of subjects (selection was based on subject's willing to pay for the
procedure) showed statistically significant decreases in total cholesterol
(median=206 vs. median=178, p=.009, n=12), LDL cholesterol (median=125 vs.
median=112, p=.08, n=7), high density lipoprotein (HDL) cholesterol
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(median=57 vs. median=50, p=.05, n=8) and an increase in bilirubin
(median=0.4 vs. median 0.6, p=.002, n=ll).
Migraine Headache Changes
There were statistically significant (p<.0001) decreases in all migraine
headache characteristics from baseline to post-intervention. These included:
headache frequency, headache intensity, the headache index, and the frequency of
medication taken [Table 2.].
Fifty-one of the 54 subjects reported a greater than 40% improvement in
their headache index and a total of 35 of the 54 improved their headache index by
85-100%. The frequency of headache over four weeks was highly correlated with
headache index (r=.82), number of medications used (r=.81) and peals: headache
intensity (r=.63) at baseline. After the intervention, all three correlation were
greater than .91. Thus the frequency of headache will be used as the measure of
migraine headaches for the analysis below.
Relationship Of Dietary Fat Intake And Migraine Headache
A strong association between fat consumption and headache frequency was
seen at baseline (Ri = .44, p=.02) using reduced monotonic regression analysis
[Figure 2.]. Subjects consuming less than 69 g of fat had an estimated mean of 5.4
headaches, compared to 10.0 for subjects consuming at least 69 g. The association
between fat consumption and headache frequency was not significant at the end
of the study. Blood nutrient levels were obtained from a small number of
individuals at baseline (N=12) and at the end of the study (N = 14). Of the 29
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nutrients examined, only bilirubin and HDL had correlation’s with headache
frequency that were significant at alpha=.10 for both periods. Bilirubin was
negatively correlated with number of headaches (r=-.65 and -.62), while HDL was
positively correlated (r=.68 and .52).
Discussion
This study demonstrates that dietary changes resulting from counseling
volunteers suffering from chronic migraine headaches to reduce the intake of fat
was associated with significant decreases in headache frequency, intensity,
duration and medication intake. The reported diets changed dramatically, with
reductions in fat intake being the largest changes seen. The validity of the selfreported diet histories is supported by both physical measurements of weight loss
and reduction in percent body fat and lower blood lipids. Moreover, a significant
association was seen at baseline between fat intake and headache frequency
across subjects.
The potential utility of this intervention strategy has strong support in the
literature. Researchers have noted that lower free fatty acids and other blood lipid
levels minimize platelet destruction and subsequent changes in serotonin levels
[6,10], resulting in fewer migraines. Other studies have indicated that the
ingestion of fatty foods (fats, fried foods, chocolate) increase the occurrence of
migraine attack [32,33], even though dietary fat was not the major thrust of the
research. Medina and Diamond previously reported that there was no dietary
effect on migraine headache; however foods in their study were categorized by the
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amount of tyramine rather than fat [34]. Analysis of the two food grouping shows
that they consisted of similar amounts of fatty food. If it is indeed the fat content
of the diet that is critical to the frequency and intensity of migraine attacks then
the Medina and Diamond findings are not surprising. Our study followed known
non-pharmacological recommendations for decreasing blood lipids; that is,
through a low fat diet [12,35-37].
Other specific mechanisms of migraine headache formation are consistent
with our findings. First, reduction of dietary intake of linoleic acid can cause a
decrease in prostaglandin synthesis [19], particularly the potent vasodilator
prostacyclin PGI-2 [38]. Secondly, when dietary fat intake is decreased, satiation is
usually achieved by an increase in the ingestion of carbohydrates. Increased
intake of dietary carbohydrates has been shown to increase the availability of
tryptophan and vitamin B6 that are important components in serotonin formation
[39-42].
The age of the study subjects (median = 41) was representative of the
general population [43] who suffer from migraine headache. According to Stang et
al. [3], the highest prevalence of migraine headache occurs between the ages 2544; this age group constituted 60% of our sample. Our study excluded smokers,
diabetics, and women with pregnancies beyond the first trimester in order to
control for some of the more obvious factors that affect lipid profile or the
nocturnal hypoglycemia that may precipitate migraine headache [44-46]. The
study was conducted over a 12 week period, with three consecutive 28 day
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sequences in order to minimize confounding due to headaches associated with
menstrual cycle phase. Possible effects of geomagnetic or other meteorologic
factors on headache [47] was minimized by staggering enrollment into the study
over a 3 month period followed by the additional 4 months of the study itself.
Since the subjects who dropped out of the study had fewer migraine headaches, it
appeared that subjects with greater migraine headache discomfort and longer
period of suffering were more willing to try a new approach to diminish their pain.
We believe that our study demonstrates that a decrease in dietary fat can
be effectively used as a treatment modality in decrease the frequency, severity and
duration of migraine headache. Further research is needed to identify the ideal
composition of the dietary fat as well as a possible intake threshold.
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Figure 4.1 Dietary changes between basehne and post-intervention
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Table 4.1 Changes in percent of body fat, weight, and headache indicators
between basehne and post-intervention
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Figure 4.2 Dietary fat and days with headache
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CHAPTER 5
OTHER FINDINGS
Results
Changes in Blood Tests
During the research study a blood test was administered to a limited number
of subjects (baseline N=12 and at the end of the study N=14). The blood test
records were collected only from subjects who received a refund from their
insurance company, or who willingly wanted to pay for the test. The first blood
record data were collected before the study began or during the baseline. The
second collection of data from blood tests from all 14 subjects were taken at the end
of the study in the post-intervention period. Changes in blood tests between the
baseline period and the post-intervention period showed a statistically significant
decrease in high density lipoprotein (HDL) cholesterol (median=57 vs. median=50,
p=.05), total cholesterol (median=206 vs. median 178, p=.009), a borderline change
in low density lipoprotein (LDL) cholesterol (median=125 vs. median=112, p=.08),
and an increase in total bilirubin (median=0.4 vs. median 0.6, p=.002). The other
blood test components did not show any statistically significant changes (Table 3.).
Bilirubin was significantly negatively correlated with number of headaches at
baseline and post-intervention
(r=-.65 vs. -.62), while HDL was positively correlated (r=.68 vs. .52).
Changes in Other Physical Activity
According to the questionnaire administered in the baseline and post-
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intervention periods, there was a statistically significant increase in the amount of
time subjects engaged in very light activity (median 0.5, which represents! 30
minutes, p=0.0123), and a statistically significant increase in the amount of time
patients were engaged in moderate activity (median 0.125, which represents 7.5
minutes, p= 0.0114). Other physical activity was not statistically significant and
there were no changes in heavy physical activity (Table 4.). Above described changes
in physical activity did not show any correlation’s with migraine headache and were
not involved in the improvement in headache profile noted in the study.
Additional Demographic Characteristics
In the study 10 subjects (18 %), followed a vegetarian diet. There were also a
total of eight subjects (14%) who had been on oral contraceptives longer than 1 year.
Three subjects (6%) on hormonal replacement. Six subjects (11%) were on
prophylactic headache therapy, (Table 5). All these demographic characteristics
failed to show any relationship to migraine headache.
Dietary Changes
Dietary fat intake decreased from baseline to post-intervention. The range of
fat intake during baseline was 26 -122 grams of fat per day and 9-75 grams per day
at post-intervention (Figure 4.). After the primary changes in dietary fat intake,
there were also changes in other nutrients (Table 6). The statistically significant
decreases (without kcalorie adjustment) were kcalories (-32%, p=.0001),
carbohydrates (-14%, p=.0001), protein (-27%, p—.0001), caffeine (-42%, p—.0001),
riboflavin (-19%, p=.0001), TPP (thiamin pyrophosphate) (-19%, p=.0001), niacin
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(-22%, p=.0001), phosphorus (-24%, p=.0001), sodium (-42%, p=.0001), calcium
(-20%, p=.0001), and zinc (-18%, p=.0001); and increases in fiber diet (+21%,
p=.0001), and vitamin B6 (+23%, p=.0001).
Based on to the stepwise regression procedure (based on 0.05 significance)
the following predicted headache frequency: increased total dietary fat ( R2=.52),
and after excluding total dietary total fat in the stepwise procedure the other
nutrients followed: increased saturated fat (R2 =.47), polyunsaturated fat (R2 =.59),
decreased vitamin B6 (R2 =.53), decreased water intake (R2=.55), and increased
sodium (R2 =62).
Anthropometric Changes
Between baseline and post-intervention there was statistically significant
decrease in percent of body fat (median=-4.19, p=.0001) and weight (median -2.0,
p=.0001) (Table 7). Percent of body fat and weight were positively correlated with
all migraine headache characteristics (Table 8.).
Migraine Headache Changes
All but three of the 54 subjects improved their headache outcomes (Table 9).
There were statistically significant (p<.0001) decreases in all migraine headache
characteristics from baseline to post-intervention. These included: headache
frequency, headache intensity, the headache index, and frequency of medication
taken (Table 10, Figures 5-8). The study found a linear relationship between dietary
fat intake and headache indicators (Figure 9.).
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Discussion
Changes In Blood Test
The analysis of blood test values showed a statistically significant decrease in
HDL and HDL was positively correlated with migraine headache frequency,
intensity and duration. The Hopkin's study (1989) found that HDL cholesterol was
positively correlated with the use of butter or hard margarine and negatively
associated with use of fruits and vegetables. It is possible that, according to current
results, subjects were decreasing intake of dietary fat and increasing intake of fruits
and vegetables. The HDL can be an indicator of patients' eating habits.
The total bilirubin was negatively correlated with frequency, intensity, and
duration of migraine headache. The total bilirubin significantly increased during
the study. According to an earlier study by Guyton, (1987) the most abundant
substance secreted into bile is bile salts and bilirubin. Bile salts help in the
absorption of fatty acids. It is possible that higher levels of bilirubin helps to
decrease the level of free fatty acids in the blood. Due to decreased level of free fatty
acids the plattelet aggregability can be minimized and migraine headache
occurrence can be prevented (Anthony, 1976).
The total level of cholesterol was decreased and it was statistically
significant. Other blood lipids may exacerbate the steps for triggering migraine
headache. High levels of low density lipoprotein (LDL) cholesterol may be
etiologically related to migraine attacks (Stein et al. 1982). Glueck and others (1986)
have shown that this to be true in juvenile migraines. It is possible that the decrease
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in the blood lipid profile with mutually decrease in levels of free fatty acids may
prevent migraine headache occurrence.
Additional Demographic Characteristics
Additional demographic characteristics did not influence the results of the
study. The fact that patients were on oral contraceptives for more than 1 year could
minimize the adaptable effect of the body on the level of female hormones (estrogen
and progesterone). Research shows that estrogen withdrawal is associated with an
increase of headache intensity and progesterone therapy appears to reduce migraine
severity. The decline in estrogen levels reduces functional serotonin
neurotransmission (Davidoff, 1995). With a low fat diet, then, the level of serotonin
can increase and the withdrawal effect of estrogen triggering migraine headache can
be prevented.
Subjects on prophylactic therapy stopped the medication after four weeks of
the low fat diet. These subjects did not show any withdrawal symptoms which could
be presented as an increase in migraine headache. It is possible that the withdrawal
symptoms from prophylactic medication are prevented by decreasing or stopping
the prophylactic medication after four weeks of adhering to a low fat diet.
The additional diseases of subjects did not appear to influence the result of
the study. One subject with Hashimoto thyroiditis had been under balanced
hormonal treatment for 10 years before entering the study. The two subjects wdth
diagnosed fibromyalgia could also benefit from a low fat diet because the disease is
characterized by low serotonin level (Stratz et al.,1993). One subject wdth
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hypertension had already been on medication for 1.5 years prior to the study. In
summary, the medical histories of subjects did not appear to influence the results of
the study.
Changes in Other Physical Activity
According to study by Thompson et al. (1987) vigorous physical activity can
trigger migraine headache. Increases in the amount of time spent in moderate or
light physical activity did not show any correlation with migraine headache
characteristics.
The increase in physical activity demonstrates that patients began to feel
better and started to be more involved in physical activity. It is possible that the
decrease in migraine headache occurrence caused the increase in light or moderate
physical activity. Lockett et al. (1992) found that moderate or light activity can build
higher levels of endorphin which can increase the threshold for pain. It is possible
that this higher level of endorphin can later enhance the effect of low fat diet in
decreasing the outcome of migraine headache characteristics (Lockett et al., 1992).
However, in order to be engaged in physical activity subjects must have less
occurrence of severe migraine headache. De facto, any increase in physical activity
could lead to the increase of migraine headache (Thompson et al., 1987). It is
possible that low fat diet can prevent migraine headache triggered by physical
activity in the first place but more research is needed to test this hypothesis.
Anthropometric Changes
The study found that weight and percent of body fat decreased from baseline

83

to the post-intervention level with a corresponding decrease in frequency, intensity
and duration of migraine headache. The significant decreases in weight and percent
body fat is supportive of the subject's adherence to the low fat diet.
Increased flux of free fatty acids from abdominally adipose tissue in obesity is
considered a precursor for migraine headache (Yanagisawa, 1991; Felly et al. 1992).
Obesity is characterized by enlarged fat mass, which in turn is positively correlated
with plasma free fatty acids concentration (Groop et al., 1991). Obese patients are
more likely to have hypertriglyceridemia (Baynes et al., 1991), and visceral fat loss
is associated with improvements of serum lipid profile (Leenen et al., 1992). A low
fat diet combined with weight loss can decrease serum lipids and free fatty acids
leading to a decrease in platelet aggregability, which reduce the immediate
precursors to vasodilatation and migraine headache.
Dietary Changes and Migraine Headache Changes
All fat components were expected to decrease due to the low fat diet which
was followed by the increased intake of fruit, vegetables, legumes and other complex
carbohydrates to combat hunger.
The decrease in caloric intake was expected due to the decrease of dietary fat
intake. Due to decreased intake of calories subjects were able to decrease obesity
(weight and percent of body fat); decrease the level of blood lipids; and decrease the
occurrence of migraine headache. Because of the decrease in caloric intake there
was also a decrease in the amount of other nutrients that were consumed.
The intake of complex carbohydrates helps to increase the intake and
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bioavailability of tryptophan which is a serotonin precursor and accelerates
serotonin synthesis (Wurtman et ah, 1979). Sugar levels were expected to increase
because of the increased consumption of fruit. Hypoglycemia is described as one of
the triggers in migraine headache (Davidoff, 1995). The current study shows
increases in sugar intake (probably from complex carbohydrates) and fiber intake
may keep the sugar in balanced level and prevent hypoglycemia. The increase of
fiber in the diet was expected because of the increased intake of fruit, vegetables,
legumes and grains in order to prevent hunger. Antioxidants were expected to
increase because of the increased intake of fruit and vegetables which are high in
antioxidants. Vitamin A has an antihyperlipidemic effect (Davidoff, 1995). In the
current study the consumption of vitamin A increased and was statistically
significant. It is possible that vitamin A can decrease the occurrence of migraine
headache because of its antioxidative characteristics by improving the blood lipid
profile. Vitamins in the B complex group were expected to increase because of the
increased intake of complex carbohydrates, cereals, and grains in order to prevent
hunger. The increased intake of vitamin B6 was expected. Vitamin B6 is an
important part of the enzyme pyridoxal phasphatase reaction in the synthesis of
serotonin, may help to decrease migraine headache occurrence (Wurtman et al,
1979). A low level of vitamin B6 can lead to a decrease in the action and in the
concentration of enzyme pyridoxal phosphate, and consequently can decrease the
production of serotonin (Davidoff, 1995). The current study found a statistically
significant increase in vitamin B6 consumption and its negative correlation with
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migraine headache occurrence.
The amount of protein consumption decreased, probably due to a decrease in
consumption of fatty animal products. The amount of consumed vitamin B12
decreased due to a decreased consumption of fatty animal protein (meat). Phosporus
is contained in meat products. It could be that due to the decrease of fatty animal
products phosphorus intake also decreased. The decrease of sodium can be
explained due to the decreased consumption of meat products which are high in
sodium (RDA, 1989). The statistically significant decrease in sodium was positively
correlated with migraine headache occurrence.
The increased intake of water may be explained by the intervention advice
given to subjects. Subjects were advised to increase water intake and to decrease
their consumption of caffeinated beverages. The statistically significant increase in
water intake and its negative correlation with migraine headache can be explained
by the effect of water on improving the blood flow in the vessels. The increase of
water intake may prevent high consumption of caffeinated beverages. The goal of
the intervention was to decrease the intake of coffee and to have the subjects drink
water instead. The connection between the consumption of coffee and the increased
occurrence of migraine headache is well known (Fennely et al.,1991). Consumption
of coffee leads to an increase of cholesterol, blood lipids and free fatty acids. In the
present study the consumption of coffee decreased and was statistically significant.
The increase intake of a fiber diet shows the decrease in the consumption of
fatty foods and also the lowering effect on blood cholesterol and other blood lipids
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(Swain et al., 1990). The increase of fiber in the current study is statistically
significant.
Conclusion
The study by Albea (1993) found that migraine may represent a risk factor
for cardiovascular disease. Perhaps migraine headache is a precursor for the later
development of chronic cardiovascular disease. Migraine headache may be a
warning signal of imbalance in the body due to the increased or decreased amount
of dietary nutrients important for keeping a healthy balance in the body. It is
possible that a similar diet (Report on Nutrition and Health, 1989) recommended
for cardiovascular patients might minimize the occurrence of migraine headache.
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Figure 5.4 Reduction in fat intake per subject
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Figure 5.5 Reduction in headache frequency
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Figure 5.6 Reduction in headache intensity
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Figure 5.7 Reduction in headache index
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Figure 5.8 Reduction in medication
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Figure 5.9 Linear relationship between dietary fat intake and headache indicators
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Table 5.3 Changes in blood tests (baseline - post-intervention)
A Median

Cholesterol mg./dL

Total
Number
of Subjects

19 median! = 206

Type of
Chang
e

12

*p-value

p=0,0093

median? = 178
Triglycerides mg/dL

9

HDL mg/dL

5

+

11
median, =57

p= 1,0000

8

p=0,0469

7

p=0.0731

median? =50
LDL Cholesterol mg/dL

2

median j = 125
median? =112

VLDL Cholesterol mg/dL

4

3

+

p=0.7500

Sodium mEq/L

0

10

0

p=0.8300

Potassium mEq/L

0.05

10

p=0.9844

Chloride mEq/L

0.5

10

p=0.9844

Magnesium mg/dL

0.2

2

Phosphorus mg/dL

0.05

10

p=01.700

Total iron mcg/mL

4

5

p=0.8125

Calciinn mg/dL

0.1

10

p=08242

Glucose mg/L

3

12

BUN mg/L

2

11

p=0.1992

Creatinine mg/L

0.05

12

p=0.4258

Uric Acid mg/L

0.15

10

p=0.8400

Total protein g/dL

0.1

11

Albumin g/dL

0.1

11

Globuhn (Calc) g/dL

0

9

0

p= 1.000

LDHU/L

7

10

+

p=0.6953

SCOT U/L

0

11

0

p=0.6500

SGPT U/L

1

11

p=0.2900

Aik. Phos. U/L

2

10

p=0.6200

GGTP U/L

5

8

p=0.1875

Total bilirubin mg/dL

0.1 median! =0.4
median? =0.6

11

* Willcoxon SGN Rank Test
Medianj (baseline) (Absolute numbers)
Median2 (post-intervention) (Absolute numbers)
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+

+

+

p= 1.0000

p=0.1436

p=0.4700
p=0.3379

+

p=0.0020

Table 5.4 Changes in physical activity between baseline and post-intervention
Median

* p=value

0.083

Standard
Deviation
1.196

0

0.9144

Sitting or standing still; eating,
watching TY writing, reading,
sewing, typing, desk work

-0.437

2.101

0

0.1157

Very light activity; driving a car,
slow walking on level ground,
most office work, laboratory
work, playing musical
instruments

-0.307

2.222

-0.25

0.0941

Light activity; normal walking
(2.5 to 3 mph), most housework,
electrical trades, carpentry, golf,
sailing, table rennis, volleyball,
active gardening (raking,
weeding)

0.351

1.970

0.5

0.0123

Moderate activity; Brisk walking
(3.5 to 4 mph), heavy
construction, hard gardening
(hoeing, digging), loading and
stacking bales, cycling, skiing,
tennis, active dance

0.298

0.844

0.125

0.0114

Heavy activity; tree felling, work
with pick and shovel, basketball,
x-c skiing, running, hill climbing
with a pack, fast swimming

-0.001

0.291

0

1.0000

Physical activity status; hour
per day in each category
Sleeping or lying still; relaxed,
napping, lying down watching
TV

Mean
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Table 5.5 Demographics

#(%)

Male

12 (22.2%)

Female

42 (77.7%)

Vegetarian

10 (18.0%)

Oral Contraceptives

8 (14.0%)

Hormonal Therapy

3 (6.0%)

Prophylactic Therapy

6 (11.0%)

Total number of subjects: 54
Median age (range): 41 (24-71)
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Table 5.6 Dietary changes between baseline and post-intervention

w/o Kcal adj’d

with Kcal adj’d

nutrient

median p-value median p-vaJuc

Kcal

-0.16

0.0001

CHOgm

-0.07

0.0001

%
chug
-32%

+0.09

0.0001

-14%
-27%

Protein gm

-0.13

0.0001

+0.02

0.1802

Fat gm

-0.38

0.0001

-0.23

0.0001

-59%

Poly gm

-0.43

0.0001

-0.27

0.0001

-63%

Sat gm

-0.44

0.0001

-0.28

0.0001

-63%

Choi mg

-0.33

0.0001

-0.18

0.0001

-53%

OLFA gm

-0.43

0.0001

-0.27

0.0001

-63%

LIFA gm

-0.59

0.0001

-0.43

0.0001

-74%

Trypt gm

-0.06

0.0781

+0.09

0.0001

-13%

Tyrosin gm

-0.04

0.3079

•►0.12

0.0001

-8%

1120 gm

-0.02

0.9155

+0.14

0.0001

-4%

Ouflcin gm

-0.24

0.0001

-0.04

0.0773

-42%

Alcohol gm

0.00

0.0041

+0.16

0.0049

0%

+0.02

0.9628

+0.18

0.0001

-►4%

Sugar gm
Fiber gm

+0.08

0.0001

+0.24

0.0001

+21%

VitEmg

-0.24

0.0001

+0.08

0.0796

-42%

ViL A IU

+0.04

0.2365

+0.19

0.0001

+9%

VitCmg

0.00

0.0430

+0.01

0.0301

-0.5%

Ribofl. mg

-0.10

0.0001

+0.07

0.0042

-19%

ViLB6 mg

+0.09

0.0296

+0.24

0.0001

+23%

Vt. B12 Ug -0.16

0.0003

0

0.7565

-31%

ViL D IU

-0.09

0.0859

+0.06

0.7244

-20%

TPP mg

-0.09

0.0001

+0.07

0.0014

-19%

Niacin mg

-0.11

0.0001

+0.05

0.0557

-22%

Folacin Ug

+0.01

0.8551

+0.17

0.0001

+3%

P mg

-0.12

0.0001

+0.04

0.0031

-24%

Fe mg

-0.06

0.0001

+0.10

0.0001

-14%

Cr mg

-0.05

0.0716 +0.04

0.1016

-12%

K mg

0.00

0.6803

+0.16

0.0001

-1%

Na mg

-0.24

-0.08

0.0067

-42%

Ca mg

-0.1

0.0001

+0.07

0.0610

-20%

Mg mg

-0.04

0.0270

+0.11

0.0001

• 10%

Zn mg

-0.09

0.0001

+0.07

0.0116

-18%

0.0001
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Table 5.7 Changes in percent body fat and weight

Difference in % of body fat between baseline and post-intervention
median

Ql

Q3

p-value

-4.19

-5.96

-2.62

0.0001

Wilcoxon Sign Rank Test

Difference in weight between baseline and post-intervention
median

Ql

Q3

p-value

-2

-4.25

1

0.0001

Wilcoxon Sign Rank Test
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Table 5.8 Correlation between dietary fat, percent body fat and headache
indicators

A dietary fat / A migraine headache — correlation
A % body fat / A migraine headache -- correlation

Frequency
(p-value)

Intensity
(p-value)

Headache
Index
(p-value)

Medication
(p-value)

+0.6978
(0.0001)

+0.7245
(0.0001)

+0.6457
(0.0001)

+0.6658
(0.0001)

+0.1832
+0.3471
(0.0196)
(0.0002)
Spearman correlation coefficients

+0.2987
(0.0017)

+0.2721
(0.0005)

Dietary Fat

% Body Fat
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Table 5.9 Percent improvement in headache index (54 subjects)

% Improvement

# Subjects

>95 - 100%

21

>90 - 95%

5

>85 - 90%

9

>80 - 85%

3

>75 - 80%

4

>70 - 75%

2

>60 - 65%

1

>55 - 60%

2

>50 - 55%

2

>45 - 50%

1

>40 - 45%

1

>0%

3
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Table 5.10 Changes in headache characteristics

Frequency

Intensity

HA Index

Medication

base

post

base

post

base

post

base

post

mean

8.7

2.5

2.8

0.9

1.9

0.5

10.6

3

s.d.

6.1

3.8

.09

1.06

1.5

0.9

9.83

6.3

median

6

1

2.9

0.5

1.36

0.14

7

1

Qi

4

0

2.25

0

0.82

0

3

0

Q3

13

3

3.5

1.5

2.83

0.35

14

3

max

28

18

4.5

4.75

7.8

4.9

41

34
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CHAPTER 6
SUMMARY
Summary of Findings
This study demonstrates that dietary changes resulting from counseling of
subjects suffering from chronic migraine headaches to reduce their intake of fat was
associated with significant decreases in headache frequency, intensity, duration and
medication intake. The reported diets changed dramatically, with reductions in fat
intake being the largest changes seen. The validity of the self-reported diet histories
was supported by both physical measurements of weight loss and reduction in
percent body fat and lower blood lipids. The decrease in dietary fat can be effectively
used as a treatment modality in decrease the frequency, severity and duration of
migraine headache.
The total number of subjects who completed the study was 54, and included
more women ( 77.7%) than men (22.2%). The average age of participants was 40
years. The reported medical history of 4 subjects who suffered from various degrees
of fibromyalgia, hypertension, depression, and Hashimoto thyroiditis did not show
any distinct relationship to migraine headache. The reported intake in 6 subjects of
prophylactic headache medication in the form of antihypertensives or
antidepressants did not alter the results. The 54 subjects who successfully finished
the study reported more frequent occurrence and longer histoxy in years of
migraine headache (13 years) versus the 6 people who decided not to participate (10
years).
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There was no noticeable change in the amount of perceived stress subjects
experienced during the whole study. There was no change in the amount of time
subjects spent in heavy physical, activity. There was, however, an increased
amount of time subjects spent in light and moderate physical activity, from
baseline to post-intervention indicating that subjects felt better during the study
and were able to increase their mobility.
During the study, subjects experienced a significant decrease in weight and
percentage of body fat which was positively correlated with frequency, intensity,
duration and intake of medication of migraine headache.
The study found a decrease in total caloric intake during the study. There
was a statistically significant decrease in the consumption of dietary fat intake from
baseline to post-intervention and in other fat components such as saturated fat,
polyunsaturated fat, oleic fatty acid, linoleic fatty acid and cholesterol. Saturated fat
was most strongly correlated with migraine headache of all the dietary fat
components. The dietary fat and all fat components described above were positively
and linearly correlated with frequency, intensity, duration and intake of medication
of migraine headache. Changes in other nutrients were also noticed and were
statistically significant, such as the increase in the intake of carbohydrates, protein,
tryptophan, tyrosin, water, sugar, fiber diet, vitamin A, vitamin B6, folacin, iron,
potassium and magnesium.
There is a positive correlation to migraine headache with the folio wing
dietary intake components: total dietary fat intake, saturated fat intake,
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polyunsaturated fat intake, sodium intake. There is a negative correlation to
migraine headache with the following dietary components: vitamin B6 intake, water
intake, vitamin D intake. The study also found positive correlation’s of gender
(female) and negative correlation’s of gender (male) with migraine headache.
The study also found changes in blood test results, which was a part of a pilot
study performed only on 12 subjects. The study found a correlation between
changes in blood lipids and migraine headache. At the end of the study there was a
statistically significant decrease in the blood level of HDL, a decrease in cholesterol,
a decrease in LDL and an increase in bilirubin. The study also found a positive
correlation of HDL and migraine headache and a negative correlation of bilirubin
and glucose with the frequency, intensity, duration of migraine headache and the
use of medication.
Based on these results the first factor that appears to trigger the occurrence
of migraine headache symptoms is high fat dietary along with an increase in weight
and percentage of body fat. The solution for the decrease, prevention or elimination
of the occurrence of migraine headache can be through low fat dietary intake and a
decrease in weight and body fat levels.
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CHAPTER 7
RECOMMENDATIONS AND CONCLUSIONS
Recommendations for Intervention
Use a Closed Setting for Intervention.
The best setting for future intervention would be to conduct the study in a
closed environment, making it possible to control the level of subjects' fat intake. An
alternative solution would be to conduct the intervention on an outpatient basis in
order to provide a cooking class each week on low fat food, or to provide subjects
with a weekly supply of low fat food during the study
Decrease Dietary Fat on a Staggered Basis.
In order to decrease subjects' dietary fat intake a food analysis could be
provided after the baseline. And according to each subject’s amount of fat intake in
grams, fat intake could be decreased on a staggered basis for each week. The patient
will then gradually adapt to the taste of low fat foods. Provide the intervention for
at least a 12 week period with a 5 months of follow up to observe if subjects
continued to maintain a low fat diet. The follow up can be used for showing subjects
results and motivate them in keeping to a long-term low fat diet.
Exclude Prophylactic Headache Therapy.
Admit subjects without prophylactic therapy, or sifter four weeks of
withdrawal of prophylactic therapy, or stagger the decrease of prophylactic therapy
after four weeks of keeping to the low fat diet. This approach brings better results
in decreasing the occurrence of migraine headache because it prevents the rebound
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effect from over medication and prevents the sudden occurrence of headaches if
subjects abruptly withdraw medication. Also this approach can be used as a
motivational tool to show more clearly that low fat diet may be influencing their
headache outcome.
Provide Frequent Follow Up,
The best compliance with low fat diet can be reached by frequent follow up.
After the first appointment, subjects should continue every 2 weeks with a 30
minute follow up for headache and food diary evaluation and in order to answer
their current questions. For the first 6 weeks it would be appropriate to continue
follow up every 2 weeks, and then continue according to individual needs in a 2month or 5-month follow up.
Explain Mechanisms of Migraine Headache.
It is very important and useful to explain to subjects, by using graphs or
pictures, the biochemical changes and potential mechanisms involved in the
triggering of migraine headache by high dietary fat. This explanation should be
followed by discussion and explanations on the benefits and mechanisms of other
dietary nutrients in the occurrence of migraine headache. If subjects have a clear
and logical picture of the mechanisms they will better understand their
responsibility in dietary treatment. This approach will enhance subjects' motivation
and compliance with a low fat diet.
Provide a Support Group.
Subjects with migraine headache may, at first, wish to be treated with
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individual approach. But after the intervention with a low fat diet they seem to
welcome the opportunity to share their experiences and suggestions on behavior
modification and on changing their diet and actual lifestyle with other subjects who
suffer from migraine headaches., The introduction of a migraine headache support
group can be beneficial for subjects' future motivation and compliance with
therapeutic diet and behavioral modification.
Recommendations for Further Study
The Upper and Lower Threshold of Dietary Fat Intake
The staggered method of dietary fat intake could be used to determine the
threshold level that triggers migraine headache. The present study found that the
low fat diet may decrease migraine headache, but it is unclear whether there is an
upper threshold for dietary fat intake, which if reached decreases migraine
headache immediately. There may also be a lower threshold, if reached, will not
further decrease migraine headache.
The Importance of Optimal Percentage of Body Fat
The present study found that there is a positive correlation between
percentage of body fat and migraine headache. Further research can concentrate on
the effectiveness of a low fat diet, with an increase in light or moderate physical
activity, which might reduce body weight and body fat with a simultaneous decrease
of migraine headache.
The Exploration of Individual Components in Dietary Fat
The present study found that after controlling for grams of fat there were
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still other components of the dietary fat group which were correlated with migraine
headache outcome. The change of the individual fat group components, such as
cholesterol, polyunsaturated fat, saturated fat, oleic fatty acid (OLFA), and linoleic
fatty acid (LIFA), showed a statistically significant decrease in the present study.
Subsequent research should concentrate on individual components of fat, determine
the best balanced composition of fat compartments which reduce headache
occurrence.
The Exploration of Other Nutrients
In this study, after controlling fat in grams and components of the dietary fat
group, other nutrients were found to have changed. At the end of the study there
were changes in amount of nutrients, such as kcalories, carbohydrates, protein,
txyptophan, tyrosine, water, sugar, fiber diet, vitamin A, vitamin B6, folacin, iron,
potassium, and magnesium, which were statistically significant. All of these
nutrients need to be explored on an individual basis to further examine the
relationship to migraine headache.
The Exploration of the Relationship Between Headache Medical History and the
Later Development of Cardiovascular Disease
According to the findings of the present study, the relationship of dietary fat
intake and migraine headache are similar biochemically to the mechanisms and
etiology in cardiovascular disease. Future research should explore if migr aine
headache could be one of the first signals of a biochemical imbalance in the body,
which after a prolonged period could lead to cardiovascular disease.
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A Comparison Study of Low and High Fat Intake
Between Vegetarians and Omnivores
During the present study there were only 10 (18.0 %) vegetarians suffering
from migraine headache of the 54 migraine subjects studied. Further study should
explore if there is a difference in the prevalence of migraine headache between
vegetarians and omnivores based on the differences in the intake of fat and other
animal products. Is there a difference in improvement in migraine headache and a
difference in the potential fat intake threshold between vegetarians and omnivores?
Epidemiologic data on the prevalence of migraine headache among vegetarians on a
low fat / high fat diet is needed. The composition of the type of fat in fatty diet
(animal versus plant fat) may have an influence on migraine headache.
The Exploration of Low Fat Diet and Controlled Blood Tests
The present study administered blood tests on only 12 subjects. According to
the described theory that dietary fat intake has an influence on platelet
aggregability, further study should explore blood test results on platelets changes,
blood lipids and bilirubin, and other components in the regular blood test panel.
The blood tests should be taken before the study, after intervention, and at the end
of the study.
A Comparison Study Between the Improvements of Migraine Headache Based on
a Low Fat Diet Only or a Low Fat Diet in Conjunction with a
Complex Life Style Change Program
From the present study there was statistically significant improvement in
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migraine headache based on the reduction of dietary fat intake. Can the occurrence
of migraine headache be even further improved by a combination of low fat diet,
stress management, and by increasing the appropriate physical activity? Such a
complex program has already shown to work in many cases of other chronic
diseases. According to the theory of platelet aggregability and the theory of free
fatty acids and hyperlipidemia for triggering migraine, the combination of low fat
diet, stress management and increased physical activity should be most beneficial in
the decrease of the occurrence of migraine headache.
The Exploration of the Dietary Fat Differences Between Males and Females
Past research found that increased flux of free fatty acids from abdominally
localized adipose tissue points to obesity as a precursor for migraine headache. In
women, accumulation of viscersil fat is associated with a less favorable lipid profile
in comparison to men. If men and women consume dietary fat at the same source
amount, the level of serum lipids will be lower in men versus women. Perhaps
there is a threshold for dietary fat that is lower in men than women that will
decrease migraine headache occurrence? The present study shows that more
women than men were admitted into the study, reflective of the population, and
that the female gender is positively correlated with increased migraine headache
occurrence.
Conclusion with Review of Research Objectives
The objective of this study was to determine that a low fat diet lowers the
frequency, intensity, and duration of migraine headache, and would therefore
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decrease intake of headache medication. Another objective of the study was also to
find, through low fat diet, the inexpensive magic cure for headache. This dietary
modification would appear as an attractive intervention due to low cost, decreased
risk of addiction and dependency on pain medication, as well as decreased risk for
the development of other chronic diseases (which have already been scientifically
connected with the consumption of high dietary fat intake). Another of the study's
objectives was to make medical society aware of a new way in approaching the
treatment of migraine headache, that is, to concentrate on the etiologic factor in
dietary intake (high fat), rather than to just minimize symptoms of headache as
many pain medications do. All the above described objectives were met since the
study shows a positive correlation between low fat dietary intake and the decrease
of incidence and severity of migraine headache.
The results of the study support the research hypothesis that a low fat
dietary intake can decrease frequency, intensity, duration and the usage of pain
medication in migraine headache.
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Appendix A Advertisement

Do you hav« * froquoat

MIGRAINE?

wili use only a

dietary intervention technique for 12
«ee)cs.
Your pareicipacion m che study is free.
If you wish co participate
in ciiis research program please contact:
Zuzana Bic, M.D., Dr.P.H.
candidate. or Glen G. Blix,
Or.P.H.. M.P.H.
phone: (714) 854- 5020 or (909) 824-4575.

«•

\
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Appendix B Phone Screening Interview

1 .Name
2.Adress
3.Source of infcrmacicn
4.Age -year
5.Smoking
6.Menscruacion (oral concracepcives)
7. Diabetes I
8.Diabetes II
9. HEADACHE;
- Headache frequency
- Headache history(>l year)
- Prophylactic therapy (being in some treatment- what type?)
- Type of drugs which usually help?
- is headache diagnosed from physician?
10. CHAJLACTSE OF HEADACHE:
location(unilateral,bilateral)
duration (hours,minutes)
pain (type-pulsating,throbbing and aching or
bandlike,tension, tightening)
severity (moderate, severe, mild)
associated symptoms (nausea, vomitting, phonophobia)
family history
behavior during attack(rest in quiet room, paces and
bangs head)
time of day (any time, frequen -1 y at night, same time
each day)
aura (visual symptoms, visual distortion, visual loss precedes the headache bv 20-30 minutes)
121

aggrevacion cf headache by physical accivicy?
11. Any cyije of allergy

12 . Do chey have a primary physician,
family doccor?
13. Being cn dies lasc 3 mcnrhs?

14 . Consumpcion of coffee
IS . Obesity (weight)
IS. Any hormonal treatment (thyroid etc.)

Given information to the person:

- ?heUsLdy1SiuabehLinCerVen“°n technique- based on diet

weeks lone
- Participants studvC°D^:P
need
a heidafhe
during the scudy,
it is a free
study. Participants don't pay and they will not be
paid
Study will start in March 1994
- We will call back in 2 weeks - to tell if a
person is eligible
■t:° our criteria for the study
will inform a person when and where
our first meeting will be
prior to the beginnina of
_**s __scudy •_ A detailed discussion of the
study will take place
at i_nat meeting where we will answer all
possible question's.
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Appendix C Intaie Interview

1. Name

2. Adress

3. ?hcne
4. Age - year of birth

5. Smoking (how many years, how many cigarentes/day, did you ever
try to quit?)

6. Have you been diagnosed with asthma, epilepsy, diabetes I. or
II. or any other diseases?

7. Do you have any type of allergy - to drugs, to food, to smoke?
Please specify that and also how the allergy is manifested such as rash, itching , not feeling well, headache? Or did you
notice any connection between drugs, food, smoke, and others,
with occurance of your headache.
Drugs ---Food
Smoke
Others

8. Do you drink coffee? How many cups/day?
9. Did you notice headache after consumption of any amount of
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alcohol? How many clases of wi',<= — — ocher cype of al
you have a week? Whac cype of alcohol do you prefer whies wine, or cchers.

10 ‘

co
ed wine,

bSS*l Cn any
durin5
lasc three norths? If v-3
of di^n^is7
name'dy
it is conducted, phone, what type

11. Did you have any hormonal treatment for anv reasons such as
problems with thyroid, or using steroids or estrocens? If you
were or are m the treatment, please state: reasons, and how
long ago it was.

12. Do yoii_take any kind of medications for any soecific reasons
excluding migraine (for example such as deoressicn, cancer,
asuhma, cardiovascular disease etc.), if yes, please soecify:
name - amount.
how long --

13. Are you vegetarian - how long and what type ( such as lactoovo
or others).

14. What is your weight/height?

15. Do you have a primary physician,
family doctor? If yes,
it you want us to contact nim/her, please write here his/her
name, phone.

16 . For women only : do you have your
menstruation regularly?
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if you had a hyscerecccmy , please ir.di cace
when
did you ncoics any connection of cccurance or
worsening of your headache with menstruation,
or hyst
tomy ?

did you notice any changes with your headache
during pregnancy?

17. For women only : Do you use oral contraceptives? If yes, please
indicate what type.

Did you notice any connection of occurance or
worsening of your headache with using oral
contraceptives? If yes, specify.

18. HEADACHE:
-- Headache frequency (how often do you have headache)
1 x a week
2 x a week
more often

specify

monthly
others
is frequency of your headache mostly same or did you notice
worsening, if yes, specify changes (such as frequency and time
when it started)
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Headache hiscory(do you have headache >1 year!
how many years have you suffered from headache?

Family history of headache - does anybody from your relatives
suffer from headache, specify

Is or was your headache diagnosed by a physician? If,yes, when
and how your headache was labeled (such as migraine tension
type, mix type etc.)

Have you been on any prophylactic (preventive) therapy or been
in some treatment or stayed in hospital for headache treatment
-- specify treatment.

Have you been in hospital for emergency treatment because of
your headache? How often?

What type of drugs did you use (or shots). Did they work or
not work:
brand name:

Type of drugs you ussually take:
brand name and amount:

Which drugs do you feel are most helpful?
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19. CHARACTER OF HEADACHE
Where is your headache usually located ?
left. unilateral,bilateral)

(specify : right,

What is the duration cf your headache ? (specify:
hours,minutes,days)

Kow can you characterize your pain (type-pulsating, feelinc vour
all blood vessels pulsating in your head ,throbbing or achinc
or bcindlike, tension, tightening)

now can you describe the severity of your headache? (moderate,
severe, mild). Which are more frequent?

Associated symptoms (nausea, vomitting, lightphobia
phoncphobia - noise), are these symptoms occuring alwavs,very
orten or sometimes

What is your usual behavior during attack (rest in quiet dark
room,or pace and bang head)

When do you usually get your headache , specify the time of day
(any time, frequently at night, same time each day or others)

Do you have any aura (visual symptoms, visual distortion,
visual loss) -- which precedes the headache by 20-30 minutes)
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Sid you ncoira agcrevacion of headache by physical accivicy‘
Or did you nccice chac your headache worsen during any ryse cf
physical accivicy? Specify che physical acrivicy.

20. For people on prophylactic (preventive) therapy only:
In case we need you to withdraw from your prophylactic therapy,
will you be willing to do so?

Would you like us to contact your primary physician and to be
in contact with him/her during the whole study? If yes, please
write the name and phone.
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Appendix D. Informed Consent
Sctiool of Public Health
Loma Linda University
Lama Linda,Ca 92350

Z&£or»*d Consent for Participants in Migraine Project.

ride: Impact of dietary Components on Incidence of Migraine
Headache.

1. I have been told that the scientific literature describes diet
as a major influence on and possibly one of the key factors m
triggering migraine. I have been told that the purpose of this
study is to determine if a balanced healthy diet will decrease
intensity, duration, and frequency of migraine headaches.If this
occurs, the usage of pain killers may be minimized.

2. I have been told that the expected duration of the study is for
12 weeks. I have been told that I will be asked to maintain
dietary, headache and drug diaries for the 12 weeks of the study.
I have been told that if is expected from me to answer the
following questionnaires: headache questionnaire, percieved
stress scale and food frequency questionnaire during the first
and last meeting. I have been told that on the first meeting
it is also expected from me to answer the basic review
questionnaire about my headache, other diseases, and other
treatments. I have been told that all information given by me
will be confidential. During the 12 weeks the following will
be done: every 4 weeks measurements for weight/height, and body
fat by skinfold measurements will be taken. The methods of
skmfolds measurements have been explained to me in detail as
non-invasive measurements. I have been told that it is optional
for..every 4 weeks to take blood and urine samples. I have been
told that blood drawing and urine samples will be taken only
from participants who agree (to a maximum of 10 people in the
study') . I have been told that I am eligible to stay in the
study even without agreeing to the optional procedures of *blood
drawing and urine sample taking.

Page i of 4
LouaUhda University
void arm
4. fJ""
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3. I have been told that there is minimal potential risk to
in this study. The diet has been recomeended by
several groups, including the Surgeon General, as healthy.
4. I have been told that optional blood sampling will be provided
by licenced venepuncturist according to standard procedures m
the participating doctor's office. Weight/height and body fat
will be measured by a research investigator (M.D.degree). I
understand that the optional blood sampling may cause slight
pain and minor bruising at the site of the needle insertion
and possible lightheadedness upon arising after blood is drawn.
5. I have been told that this experimenet does not use any drugs,
and is based on a change of diet which has been described in
scientific literature as beneficial for overall health. I have
been told that the potential benefits for me are decreased
intensity,duration, and frequency of migraine, and minimized use
of pain cablets and treatment. I have been told chat during the
12 week study, it is possible that I may lose some weight. This
diet keeps all nutrients levels in reconmended RDA amounts.
6. I have been told chat because of the different factors causing
patients' headaches,and the experimental nature of this study,
chat I may not benefit from this study and have a decrease in
headaches.
7. I have been told that if I wish, the research investigators
can contact my primary physician.I understand that the research
investigators will contact ray primary physician only with ray
agreement.
8. I have been cold that the voluntary nature of participation
allows me the freedom to withdraw at any time without penalty or
jeopardizing medical care, and that I can terminate at any
time if I feel uncomfortable (such as worsening of migraines or
other health complications) or according to suggestion of ray
primary care physician. If I or my physician feel that being in
the experiment is no longer in ray best interest, the research
diet will be stopped and further treatment will be discussed.
9. I have beer, told that in case of worsening migraine headache,
the. alternative
will be to withdraw from the experiment study
.
and go back on prophylactic drug therapy, if I used this before,
or withdraw and discuss with my primary physician the
potentials for prophylactic drug use.

Page 2 of 4
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16. I have been given a copy of this consent.

” ■ imViss?

& sinTA.X'ss?1j-s- ■ •

18. I have not participated in any research study within the past

3 months on the subject of diet.

Slgnlcure of Participant

Data

Witness

Data

Signitura of Zxivestigator

Phone nuaaber

Data

Page 4 of 4
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Appendix E. Perceived Stress Scale
tJM following *lt«ra<»ti*«* :

For •oc* qu«atloaf chaooo fx<

0 • N«v«r
1 • Alsoac Haver
2 • SoMriaaa

3 “ Fairly Often
4 • Very Often

1. Zn th« last few weeks. how often have
you been upset because of soseching
that happened unexpectedly?

0

1

2. In the last few weeks, how often
have you felt that you were unable
to control the important things
in your life?

0

1

2

8.

1

0

In the last few weeks, how often
have you felt nervous and ‘stressed"?

4. In the last few weeks, how often
have you dealt successfully with
Irritating Ilfs hassles?
5. In the last few weeks, how oftsn have
you felt that you were affectively coping
with Important changes that were
occurring In your life?

3

4

2

3

4

2

3

4

12

3

4

-01234

4, Zn the last fsw weeks, how often ha we
you felt confident about your ability
to handle your personal probleee?

0

12

3

4

7. In the last few weeks, how often have
you felt that things wars going
your way?

0

12

3

4

t. In the last fsw weeks, how often hawe
you found that you could not cape with
all the things that you had to do?

0

12

3

4

9. Zn the last fsw weeks, how often have
you been able to control Irrltatlone
In your life?

0

12

3

4

10. In the fsw weeks, how often have
you fslt that you were on top of
things?

0

12

3

4

11. In the few weeks, how often have
you been angered because of things
that vere outside of your control?

0

12

3

4

12. Zn the last fsw weeks, how oftsn have
you found yourself thinking about
things that you had to accomplish?

0

12

3

4

13. In the last few weeks, how often have
you been able to control the way you
spend your tlaa?

0

12

3

4

14. In the lest fsw weeks, how often have
you. felt difficulties were piling up
so high that you could not over roe e thee?

0

12

3

4
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Appendix F. Physical Activity Questionnaire

Physical Activity Status - indicate how many hours
per day you typically spend in each of the following
categories. If your activity level fluctuates, use average
values. Total must equal 24 hours. Decimals can be used
(eg. 30 mm. =0.5 hrs.)

15.
16.
17.
18.

19.

20.

Sleeping or lying still; relaxed, napping,
lying down watching TV
Sitting or standing still; eating, watching TV,
writing, reading, sewing, typing, desk work
Very light activity; driving a car. slow walking
-on level ground, most office work, laboratory
work, playing musical instruments
Light activity; normal walking (2.5 to 3 mph),
most housework, electrical trades, carpentry,
golf, sailing, table tennis, volleyball, active
gardening (raking, weeding)
Moderate activity; Brisk walking (3.5 to 4
mph), heavy construction, hard gardening
(hoeing, digging), loading and stacking bales,
cyding. skiing-tennis.~active dance
Heavy activity; tree felling, work with pick
and shovel, basketball, x-c skiing, running, hill
dimbing with a pack, fast swimming
TOTAL; must equal 24 hours
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Appendix G. Headache and Medication Profile

HEADACHE DIARY
DATE:
s
i

4

3
2

I

w

•5

2

2
I
i

1

0
4789 10 11 12
a.m.

1

2

34

5*78
p.m.

9 10 11 12

1

2

3

4

5

4.1*1.

Headache Rating Scrte:
0 = No neaoacnc
1 = Very mikJ headache, aware of it only wnen attencng to it
2 = Mitt neacacne. could oe ^nored at times
3 = Moderate headache, pan s noocaatty present
A = Severe neaoacne. dtffna* to concentrate, can oo unoemandtng tastes
5 3 Extremely ntense neadKte. ncaoaatated

1 For any day you have a headache fill out one of these tables, based on the examples
attached. ( References: Management of Chronic Headaches, A psychological approach by E.B.
Blanchard and F. Anorasik, 1985, Pergamon Press Inc.)
2. Whenever you take any medication, indicate below the type, name, number of tablets or
capsules, and the hour at which the medication was taken.
MEDICATION:
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EXAMPLE 1
HEADACHE DIARY
DATE:
5

>»

4

\

J

i

i

4

ec

!

3

♦

*

I

»

i

«
:
i

i

t

I

i

2

-i
i

1

t

:
I

0
6

7

*

9 10 11 12 1
a.m

t
i

2345*7*9 10 11121

p m.

2345

4 m

umatiart** Rating Scate:
0 = No rwacacn*
1 * Very irmo n«o»cn«. aware of it only wn«n attcnong to <
2 = mho neaoacne could 0* ^norao at arms
3 3 Mooerate mooacna. com s noocaaoiy present
4 = Severe neaoacne. difficult to concentrate, can oo unoemandmg rasas
5 = Extremely intense neaoacne. ncaoaraated

1 For any day you nave a headache fill out one of these tables, based on the examples
attached. ( References: Management of Chrome Headaches. A psychological approach by —B
Blanchard and F. Andrasik. 1985. Pergamon Press Inc.)
2 Whenever you take any medication, indicate below the type, name, number of tablets or
capsules, and the hour at which the medication was taken.
MEDICATION:
Tylenol: regular-strenght. 325 mg (each) - 2 tablets, at 11 pm.
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EXAMPLE 2
HEADACHE DIARY

DATE:.
3
I

i

i

4

=
5

3

*

*

c

*

2

1

0

*
4 7 8 4 10 11121
4.m.

234547 44 10 11121 2345
pm.
a.m.

Headache Ritmo Scatc:
C s No reaoacne
a Very rmtt neaoacne. aware of 4 only wt>eo attending to it
2 * Mea neaoacne. could oe qrcrta at tvnes
3 3 Moderate ncaoacne. pen a nenceaoiy present
a a Severe neadacne drfficutt to concentrate can do unoemanong tastes
5 3 Exiremery intense naaoacne. ncapacitated

i For any day you have a headache fill out one of these taWes. based on the examples
attached ( References: Management of Chronic Headaches. A psychological approach by E.B
Blanchard and F. AndrasiK. 1985. Pergamon Press Inc.)
2. Whenever you take any medication, indicate below the type, name, number of tablets or
capsules, and the hour at which the medication was taken.
MEDICATION:

Tylenol: regular-strenght. 325 mg (each) - 2 tablets, at 9 am.
Ibuprofen: 200 mg (each) - 3 tablets, at 2 pm.
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Appendix H. Food Diaries
Pan«nf* Nam«:___________
• 24 HOUR RECALL.
Oat* of Racail: _________

Food Ooocrtpaon

Salving Six*

Food Oooertptton

S*vtng SUa

Food Doocrtptlon

Soivmg Stza

Food Dooertptlon

Sorvtng Slz>

Food Oaacnptioo

Satvtng Siza

Food Poicnptton

Sonrtng Stza

Food Ooocnpuon

Sorvtng Slza

Sarrtng !!Jl
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Appendix I. Anthropometric Measurements

SKINFOLD MEASUREMENTS
(date)

NAME
AGE

HEIGHT

SEX

WEIGHT

MEASUREMENTS(mm)
CHEST

SUPRAILIAC

ABDOMINAL

MID AXILLARY

THIGH

SUBSCAPULAR

TRICEPS

MEDIAL CALF

CALCULATIONS
(USE APPROPRIATE FORMULA*

TOTAL SKINFOLDS (mm)
BODY FAT PERCENT
POUNDS OF FAT
(TOTAL WT i BOOT PAT %>

POUNDS OF LEAN BODY WEIGHT
(TOTAL WT - FAT WT)

CLASSIFICATION
(SEE NORMS)

IDEAL BODY WEIGHT
[L8W / (100% • DESIRED FAT %)|
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Appendix J. Blood Tests
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Appendix J
Blood Test

DATE COLLECTED

bate aecsved

DATE HPOffTBJ

27-JUL-94
2T-JUL-94
S : 40 AM
EVA KATZ, K-D.

26-JUL-94

4902 IRVINE CTR DR
SUITE 103
IRVINE, CA 92714

2

OF

2

A^ESSON/REQ •

•*9 1 T66T -7
Ci2T 3373-1

OJENT #

TEST REQUESTED

40491-0016
27-003
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Ii
1»

X • IX

•
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REFERENCE RANGES REFLECT ADULT VALUES
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I
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VLDL Calc. * s *
VLDL CH0LEST.(Calc.)

-» • -.2

MICH
1

14 - 46 N

•EST NAME

24

aero

UD •» 45

17-10.5,101

40 ■ 74 H

’ Z

1.5

i
iorr

SCOT
UD ■> «0

un.

1 34

z: u

iS

4.3

ENZYMES
L O H
340
UO

15

4

THYROID

64 |9 9

r

1| n“*T.
I"
rtl 77 I 4.0 • 15

4 - 3D

UNITS

NORMALS

. 9

mg/dL

1.7-2.8

8 LOU

ag/dL

1 «-5C

: « X

141

3 4 . to

Appendix K. Progress Notes

Name

Dace

Please comment on:
- • Impact of program on*your headache (has intensity, duration and
frequency of your headache changed after starting the diet?)

2. Impact of program on your general well-being (how do you
percreve your health since the starting of the diet?)
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3-

re5ai‘ding the program?

143

for exitiDle^by11 having ^Withh °Ur ProSram in the future
«P

on a monthly or bimonthly basis?
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a "Headache Support

Appendix L. Intervention Materials

Dietary Recommendation-

Eat a low fat diet - keep fat on 20 g/day
No additional fat
Watching fat (low fat milk and other diary products)
Using booklet T Factor. fKatahn Et All
Using our low fat menu example (Katahan 1989 - T Factor One Mp^i at a Timp-i
Using Anderson’s exchange list (Anderson J W — Diahptes 19R2’)
To prevent hunger eat more fruit, vegetables, drink more water
Using Cooking Without Fat bv G Matelian 1QQ7

Recommended Readings
1. Low fat menu from ; The T-Factor Diet. One Meal at a Time by Martin
Katahn, Ph.D., W.W. Norton & Company
2- I-he T-Factor. Fat Gram Counter by Martin Katahn, Ph.D., Jamie Pope Cordle. M.S., R.D. W. W. Norton & Company
3- Ifre complete nutrition counter hy Lynn Sonberg, 1993, Berkeley Books New
York
4- SQwes 7 Church's Food Values of Portions Commonly l ised by Jean A. T.
Pennington, Ph.D., R. D., the 16th edition, J. B. Lippincott Company
Weigh Lsss by Dr. Dean Omish, 1993, Herper Collings Publishers
6- The. New McDouaall Cookbook by John A. McDougall, M.D., and Mary
McDougall. 1993 Penguin Books USA Inc.
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New Veqgigrign Cuisine ^250 Low Fat Recipes^ by Linda Rosensweig and
the food editors of the Prevention magazine, Rodaie Press, Emmaus,
Pennsylvania
8. FQ-Qd. Finder fthe most practical nutrient referenced by Elizabeth S. Hands
from ESHA Research, 1990, 2nd edition
9- Choking Without Fgf by George Mateijan, Health Valley Foods. 16100
Foothill BJvd., Irwindaie, CA 91706-7811
10. The Simple Soybean and Your Health by Mark and Virginia Messina Avery
Publishing Group, Garden City Park, NY
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Appendix M. Letter of Acceptance to Medical Hypotheses Journal

Medical
Hypotheses
Or 0 F Horroom
Efamol RcMwcn Instttuta.
P. 0. Sox 818. Kentvilie. Nova Scotia. B4N 4H8. Canaoa
Fax 902 678 9440 Tateonona 902/678—5534 or 3001

December 17, 1996

Dr Zuzana Bic
School of Public Health
Loma Lmda University
Loma Linda, CA
92350-0001 USA
Dear Dr Bic:
Many thanks for submitting your paper to Medical Hypotheses.
Hus has been reviewed and I am pleased to say that the reviewers have found it of
considerable interest. I congratulate you on a stimulating hypothesis which I will be
happy to publish m Medical Hypotheses.
A reprint order form will be sent to you direct from the publishers.
With best wishes.
Yours sincerely,

Dr. David Horrobm
DFH/elw
ENCL.
“IN SEARCH OF THE IDEAL TREATMENT FOR MIGRAINE HEADACHE”

Pubhshar
ChurcDill Livingston*
aooerr Stevenson House '-3 Baxter’s Place. Leitn Walk. Ecinourcn EHi 3AF 'JK
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Appendix N. Letter of Submission to The New England Journal of Medicine
UNIVERSITY LIBRARY
COMA LINDA CALIFORNIA

The New England Journal of Medicine
10 Shattl’CK Street. Boston, Massachcsetts 02 1 : 5-60^4

TELE-HONE 517/734-9800

EDITORIAL OFFICES

1-800/445-8080
FAX 517/739-3864

February 6, 1997

Manuscript No. 97-0348
Zuzana Bic M.D., Dr.P.H.
24 Los Trancos
Irvine CA 92612
Dear Dr. Bic:

Thank you for submitting your manuscript for possible publication in
the Journal. Please use the manuscript number and the name of
the first author in all future correspondence or telephone
conversations concerning this nanuscript. You will be notified
of our decision as soon as possible.
we are undertaking evaluation of your nanuscript with the understanding
that neither the substance of the article nor the figures or tables
have been published or will be submitted for publication elsewhere
during the period of review.
This restriction does not apply to abstracts published in connection
with scientific meetings or to news reports based on presentations
at such meetings. There is no objection to answering questions
from reporters that are intended to clarify such presentations,
but authors of papers presented at meetings should not distribute
copies of their nanus cripts or otherwise encourage premature publication
of the details of their work. The Journal's policy is explained more
fully elsewhere (NEJM 1991; 325:1371-2 and 1994; 330:1608-9).
In addition, copies of published papers or manuscripts in preparation
or submitted for publication elsewhere that are related to or overlap
with this manuscript in any way should be submitted to the Editor.
Please contact my office if you have any questions about these policies.
Sincerely yours,

^ Jercne P. Kassirer, m.D
Editor-in-Chief
JPK/jlm
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